


AD-A248 904



2

GRANT NO.: DAMD17-90-Z-0033

TITLE: PHYSICAL CHARACTERIZATION OF CLOSTRIDIUM BOTULINUM
NEUROTOXIN GENES

PRINCIPAL INVESTIGATOR: NIGEL P. MINTON

PI ADDRESS: Public Health Laboratory Service
Center for Applied Microbiology & Research
Porton Down, Salisbury, Wiltshire, SP4 0JG,
United Kingdom

REPORT DATE: February 17, 1992

TYPE OF REPORT: Midterm


20030214075

PREPARED FOR: U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND
FORT DETRICK
FREDERICK, MARYLAND 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The findings in this report are not to be construed as an
official Department of the Army position unless so designated by
other authorized documents.

92-09806



REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
<small>Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.</small>				
1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE February 17, 1992	3. REPORT TYPE AND DATES COVERED Midterm 2 Jul 90 - 1 Jan 92		
4. TITLE AND SUBTITLE Physical Characterization of <u>Clostridium botulinum</u> Neurotoxin Genes		5. FUNDING NUMBERS DAMD17-90-Z-0033 61102A 3M161102BS12 AA DA335530		
6. AUTHOR(S) Nigel P. Minton				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Public Health Laboratory Service Center for Applied Microbiology & Research Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom		8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research & Development Command Fort Detrick Frederick, Maryland 21702-5012		10. SPONSORING/MONITORING AGENCY REPORT NUMBER		
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) DNA fragments encompassing the neurotoxin genes of <u>Clostridium botulinum</u> types B and E have been cloned and their entire nucleotide sequences determined. Similarly, recombinant clones carrying all but the extreme 5' end of the type F gene have been obtained and analyzed by nucleotide sequencing. The current sequence does not encompass the first 20, and terminal 60, codons of the structural gene, and is not fully authenticated with regard to PCR-induced errors. Attempts to clone the type G gene were unsuccessful. A total of 20 different strains of <u>Clostridium sporogenes</u> were examined as potential hosts for expression of toxin gene subfragments. In no case was DNA transfer demonstrated, either by electroporation or by conjugative mobilization. Attention was switched to employing <u>Clostridium acetobutylicum</u> NCIB 8052 as the recombinant host and efforts focused on obtaining regulated expression of a previously constructed <u>lac</u> promoter. Some progress towards this aim was made by devising a strategy whereby heterologous DNA may be "forced" to integrate into the <u>C. acetobutylicum</u> chromosome.				
14. SUBJECT TERMS <u>Clostridium botulinum</u> ; Neurotoxin genes; Gene cloning; Nucleotide sequencing; DNA transfer; Gene expression; RA 1			15. NUMBER OF PAGES	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

_____ Where copyrighted material is quoted, permission has been obtained to use such material.

_____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

NPM Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

NPM In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

_____ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

NPM In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

NPM 17/02/92
PI - Signature Date

Accession For	
NTIS Serial	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A-1	



CONTENTS

	<u>Page Number</u>
INTRODUCTION	1 - 6
1. NATURE OF THE PROBLEM	1
2. BACKGROUND OF PREVIOUS WORK	2
3. PURPOSE OF THE PRESENT WORK	3
4. METHODS OF APPROACH	4
4.1 Development of a Clostridial Expression System	4
4.2 Cloning of Botulinum Neurotoxin Genes	6
BODY	7 - 56
1. CLONING OF THE BoNT GENES	7
1.1 Materials & Methods	7
1.2 Cloning/ Sequencing of the BoNT/E Gene	9
1.3 Cloning/ Sequencing of the BoNT/B Gene	18
1.4 Cloning/ Sequencing of the BoNT/F Gene	26
1.5 Cloning/ Sequencing of the BoNT/G Gene	31
1.6 Amino Acid Homologies Between Characterised Neurotoxins	31
2. EXPRESSION SYSTEM DEVELOPMENT	39
2.1 Materials & Methods	39
2.2 Gene Transfer in <i>Clostridium sporogenes</i>	41
2.3 An Expression System for <i>Clostridium acetobutylicum</i>	47
CONCLUSIONS	57 - 58
REFERENCES	59 - 64

CONTENTS

Page Number

TABLES

1.	Oligonucleotide primers employed in PCR of type E DNA	11
2.	Amino acid homology between BoNT H and L chains	32
3.	Susceptibility of <i>C. sporogenes</i> strains to various antibiotics	42
4.	Transformation frequencies with various electroporators	43
5.	Percentage survival of <i>C. sporogenes</i>	44
6.	Growth of NCIB 8052 (pMTL500ET) in the presence of Tc	51
7.	Segregational instability of pMTL513E	55

FIGURES

1.	BoNT/E gene cloning strategy	13
2.	Complete nucleotide sequence of the type E gene	15
3.	Strategy employed in the cloning of the <i>botB</i> gene	20
4.	The cloning vector pMTL32	21
5.	Complete nucleotide sequence of the type B gene	23
6.	BoNT/F gene cloning strategy	27
7.	Partial nucleotide sequence of the type F gene	29
8.	Phylogenic relationships between BoNT H and L chains	33
9.	Full alignment of all known clostridial neurotoxins	34
10.	Neurotoxin hydrophobicity plots	37
11.	The <i>Clostridium/ E. coli</i> shuttle vector pMTL500ET	45
12.	The <i>C. acetobutylicum</i> expression vector pMTL500F	48
13.	Inducible expression of a <i>cat</i> gene using pMTL500F	49
14.	The <i>C. acetobutylicum</i> <i>gut</i> operon	53
15.	Cloning vectors based on the pAMB1 replicon.	54
16.	pMTL513E-based integration at <i>gutD</i>	56

INTRODUCTION

1. NATURE OF THE PROBLEM

The often fatal condition of botulism is caused by a group of highly toxic proteins (botulinum neurotoxin, BoNT) produced by certain species of clostridia, principally *Clostridium botulinum* (Sugiyama, 1980). On the basis of their serological properties, seven distinct types of BoNT are recognised, and have been designated BoNT/A to G. They exert their effects on vertebrates by blocking the release of the neurotransmitter acetylcholine in presynaptic nerve termini, resulting in neuromuscular paralysis (Habermann and Dreyer, 1986; Simpson, 1989). Although BoNT is synthesised as a single polypeptide chain (M_r approximately 150,000), proteolytic cleavage generates the more toxic dichain form, in which a 50 000 Da polypeptide light (L) chain and a 100 000 Da heavy (H) chain are linked by a disulphidryl bridge. The different types of *Clostridium botulinum* exhibit differential efficiencies in nicking of the single chain to the dichain form. Thus, BoNT/A exists principally as a dichain, BoNT/B exists as a mixture of predominantly single chain with some dichain, whereas BoNT/E is found essentially only in the single chain form (Dasgupta, 1990). Purified single chain toxin may be converted to the dichain form *in vitro* by proteolytic cleavage with trypsin (Dolly et al., 1984).

The overall structure and mode of action of BoNT is shared by a second clostridial toxin, namely tetanus (TeTx) of *Clostridium tetani* (Welloner, 1982). They differ in that whereas BoNT acts at the nerve periphery, TeTx blocks the release of inhibitory amino acids in the central nervous system. The neuromuscular action of both types of neurotoxin has been suggested (Simpson, 1986) to be composed of three distinct phases: (i) binding of the toxin to neurone acceptor sites; (ii) an energy-dependent internalisation stage in which the toxin, or part of it, enters the nerve cell, and; (iii) the eventual blockade of neurotransmitter release. Although the exact mechanisms involved remain poorly understood, it is generally assumed that the L chain possesses the pharmacological activity (Bittner et al., 1989; Ahner-Higler et al., 1989) and the H chain is responsible for binding of the dichain to cell surface acceptors and thereafter internalisation through the cell membrane (Simpson, 1989). Some evidence has been obtained suggesting that the channel forming activity resides in the NH_2 -terminal portion of the H chain (Mochida et al., 1989; Poulain et al., 1990) and acceptor recognition sites in the $COOH$ -terminus (Morris et al., 1981; Shone et al., 1985; Kozaki et al., 1987; 1989).

The effectiveness of modern food-preserving processes in Western countries has made

outbreaks of botulism extremely rare. The frequent use of *C. botulinum* as a test organism in the food industry, and the growing use of the toxin by neurobiochemists, has, however, led to the development of human vaccines. The formulation of these vaccines has changed little since the early 1950s: partially purified preparations of the neurotoxins are toxoided by formaldehyde treatment and absorbed onto precipitated aluminium salts. Using such methodology, polyvalent vaccines (against ABCDE or ABEF) for human immunisation are currently available. Such vaccines suffer from the drawback of low immune response and considerable batch to batch variation due to the high proportion (60-90%) of contaminating proteins in toxoid preparations. Recent work has therefore concentrated on the development of procedures for the purification of toxins to near-homogeneity. This has been achieved with all but type G toxin (Shone *et al.* 1985; Evans *et al.*, 1987; Schmitt *et al.*, 1986). The use of purified toxins in the production of vaccines, however, suffers from the drawbacks of having to produce them under high containment and requires the presence of low levels of formaldehyde to prevent possible reversion of the toxoid to the active state.

2. BACKGROUND OF PREVIOUS WORK

Production of subunit vaccines have been investigated by a number of laboratories. In general, individual toxin subunits produce poor immune responses. A non-toxic fragment comprising the L-chain and the N-terminal portion of the H-chain (analogous to the AB fragment of tetanus toxin) of type A toxin has been shown to produce an immune response in guinea pigs comparable to the entire toxin (Shone and Hambleton, 1989). It has therefore been argued that production of such a toxoid polypeptide by recombinant means provides an excellent candidate for future vaccines. This would most simply be achieved by insertion of the appropriate coding sequences into specialised bacterial vectors, which then direct the expression of high levels of the protein in suitable bacterial hosts. The unparalleled sophistication of recombinant procedures and vectors of *E. coli* has resulted in this enterobacteria being the organism of choice in such processes. There are, however, a number of factors which suggest that *E. coli* is not the best candidate for undertaking the expression of clostridial toxin genes.

Although clostridial genes are reported to express moderately well in *E. coli* (reviewed by Young *et al.*, 1989), this finding only applies to genes isolated from mesophiles encoding proteins substantially smaller (c. 30-40, 000 Da) than BoNT, or thermophilic genes (eg., from *C. thermocellum*) whose G + C content closely matches that of *E. coli*. Attempts to express clostridial genes encoding large polypeptides have met with either very limited success (eg., type A toxin of *Clostridium difficile*; Von Eichel-Streiber, 1989) or total failure (eg., the bacteriocin of the *Clostridium perfringens* plasmid pIP401, Garnier and Cole, 1988). More

germane to BoNT have been the attempts to obtain expression of polypeptide fragments of TeTx. In the study of Eisel *et al.* (1986) various subfragments of the gene were expressed in *E. coli*, either initiating from the tetanus ATG or as fusion proteins. The levels attained were extremely poor, and it was concluded that no clone "led to the synthesis of sufficient amounts of toxin-specific protein to allow biological studies. At present these considerations argue against a large-scale production of toxoid based on genetically engineered non-toxic derivative." Similar results were obtained by Fairweather *et al.* (1986, 1987), who expressed the C-terminal portion of the toxin (43% of the molecule) to levels less than 1 % of the cell's soluble protein. More recently, attempts to express subfragments encoding either the L-chain or substantial portions of the H-chain of the type A gene have met with little success (A.H. Bingham, personal communication). A further difficulty encountered in all these studies was considerable degradation of the polypeptides produced, even in protease minus *E.coli* hosts.

The reasons for the observed inefficient expression of large clostridial toxin genes would appear complex, but the apparent translational barrier is suggested (Eisel *et al.*, 1986; Cole and Garnier, 1988) to be a consequence of the extremely biased codon usage exhibited by clostridial genes. Thus genes isolated from *Clostridium spp.* whose genomic DNA is of a high A+T content (greater than 70% A+T), exhibit an extremely strong discrimination against all degenerate codons ending in C or G, or, in the case of Ser and Arg, beginning with C. In the case of the neurotoxin type A gene (Thompson *et al.*, 1990), 86.1% of Arg codons conform to AGN rather than CGN, 69% of Leu codons conform to UUA as opposed to CUN, while overall, 90.3% of the degenerate codons end in A or U. In the tetanus toxin gene the equivalent respective figures are 92.1%, 69.3% and 92.9%. A consequence of this codon bias is that many of those codons known to act as modulators of gene expression in *E.coli* (Grosjean and Fiers, 1982) occur extremely frequently in clostridial genes. eg., the type A neurotoxin gene exhibits a 53.8% preference for AUA (Ile), 43.7% preference for GGA (Gly) and an overall 86.1% preference of AGN (Arg) modulator codons. It would appear that although *E. coli* can tolerate a certain number of such codons, as occurs in genes of moderate size, the cumulative effect of the sheer volume of modulator codons present in clostridial neurotoxin genes results in a dramatic reduction in translational efficiency. The most logical solution to these problems would be to use a clostridial host, rather than *E.coli*.

3. PURPOSE OF THE PRESENT WORK

The production of a polyvalent vaccine against all known types of botulinum neurotoxins requires the availability of large quantities of pure protein which is; (i) capable of eliciting the production of neutralising antibody in humans and; (ii) non-toxic to personnel involved in its isolation, purification and formulation into a vaccine. These criteria cannot be currently met by producing authentic neurotoxin from natural clostridial strains. Although the desired

subunit vaccine could conceivably be produced by recombinant means, as discussed above, transiational barriers suggest that *E. coli* cannot be employed as the recombinant host. A major objective of this study was therefore to develop a clostridial expression system, ideally based on a non-toxinogenic host closely related to *C. botulinum*, and test its utility by expressing various non-toxic polypeptides (principally derived from the H-chain moiety) of the type A neurotoxin. The immunogenicity of these recombinant polypeptides would then be evaluated as potential subunit vaccines. In parallel, the second principal objective has been to clone other neurotoxin genes (types B, E, F and G) and derive their complete primary amino acid sequences by nucleotide sequence analysis. Selected polypeptides of these neurotoxins could then also be produced using the recombinant host/vector system and their potential as subunit vaccines ascertained. At the end of these studies it was anticipated that a system for producing high levels of non-toxinogenic neurotoxin polypeptides will have been developed which may be used in the formulation of a general botulism vaccine against types A, B, E, F and G. Furthermore, the availability of the complete primary amino acid sequences of these toxins will facilitate future work which may be aimed at deriving vaccines based on synthetic peptides.

4. METHODS OF APPROACH

4.1 Development of a Clostridial Expression System

Our initial strategy was to choose a *Clostridium* sp., taxonomically closely related to *C. botulinum*, and formulate procedures for introducing recombinant DNA. Our choice as the host was *Clostridium sporogenes* (taxonomically considered to be a non-toxicogenic species of *C. botulinum*; Cato and Stackebrandt, 1989) and the DNA transfer procedures investigated, electroporation and conjugative transfer. The former procedure, ubiquitous in its application to Gram-positive bacteria (see Chassy *et al.*, 1988; Lucansky *et al.*, 1988), relies on the transient introduction of pores into the cell membrane, by applying an electrical discharge across cell suspensions, through which exogenous DNA may pass. We have previously used electroporation for the successful introduction of plasmids into *C. acetobutylicum* (Oultram *et al.*, 1988a), and similar protocols have been published for *C. perfringens* (eg., Allen and Blaschek, 1988). Conjugative transfer relies on mobilisation of the cloning vector into *C. sporogenes* by intergeneric matings (Trieu-Cuot *et al.*, 1987). We have constructed a plasmid, pMTL30 (Williams *et al.*, 1989), which carries the ColE1 replicon, the Gram-positive erythromycin (Em) resistance (^r) gene of pAMB1 (Brehm *et al.*, 1987), the *E. coli* *lacZ'*/multiple cloning region of pMTL20 (Chambers *et al.*, 1988), and the *oriT* region of plasmid RK2. Plasmid derivatives, in which the replication origins of either pCB101 (a *Clostridium butyricum* plasmid; Minton and Morris, 1981) or the streptococcal plasmid

pAMB1 have been inserted, have been shown to be mobilised from an *E.coli* donor to an *C. acetobutylicum* recipient at frequencies of up to 10^{-5} per donor (Williams et al., 1989a; 1989b). In our attempts to transfer DNA into various strains of *C. sporogenes* the plasmid vehicles utilised were endowed with the replicative origins of either pCB101 or pAMB1. The latter type of vector was preferred as it has proven to possess an extremely broad host range amongst Gram-positive bacteria, and exhibits a high degree of structural stability (Bruand et al., 1990; Swinfield et al., 1990). As it cannot be assumed that these replicons will function in *C. sporogenes* it was envisaged that replicons could be cloned from indigenous *C. sporogenes* cryptic plasmids into 3 different types of "in-house" Gram-positive replicon cloning vector (ie., plasmids only capable of replicating in *E.coli*). These vectors (pMTL20E, pMTL20C and pMTL20T) carry three different Gram-positive resistance genes (*erm*, *cat* and *tetP*, respectively), all of which have been shown to express in *Clostridium* spp. (see Minton and Oultram, 1988; Abraham and Rood, 1985).

Having formulated procedures for DNA transfer we proposed to endow constructed shuttle vectors with efficient transcription/ translation signals to facilitate high expression of appropriately inserted heterologous genes. Since ribosomal RNA (rRNA) operons are generally transcribed efficiently it was proposed that the rRNA genes of *C. sporogenes* would be the source of transcriptional initiation and termination signals. Once cloned and characterised the identified promoter region was to be modified by advanced genetic engineering (ie., creation of restriction sites by site-directed mutagenesis and insertion of required sequences as synthesised "units") to create an expression cartridge. This would consist of a portable restriction fragment, carrying (in sequential order): the rRNA promoter -35 and -10 elements; a synthetic *E.coli lacZ* operator sequence positioning immediately following the rRNA +1; a synthetic ribosome binding site (SD) complementary to the determined *C. sporogenes* 16s RNA; at an appropriate distance from the SD, a recognition sequence for *NdeI* (CATATG), followed by the *lacZ'*/multiple cloning sites of plasmid pMTL20, whereby the ATG represents the translational initiation codon of *lacZ'*; finally the *lacZ'* region would be followed by the transcriptional termination signals of the rRNA operon. The efficiency of the system could be tested using a suitable promoter-less reporter gene, eg., *cat*. The presence of the *lacZ* operator site should allow repression of expression during construction in *E.coli* (by the presence of the high copy number *lacI^s* plasmid pNM52, Gilbert et al., 1986), and thereafter regulated expression of the gene in clostridia. It was envisaged that this could be achieved in an analogous fashion to that used in *B.subtilis* (Le Grice et al., 1987), where a plasmid borne copy of the *lacI^s* gene is placed under the transcriptional control of a moderate clostridial promoter (we will use the *Clostridium pasteurianum leuB* promoter, cloned and sequenced in this laboratory), and induction of the rRNA expression cartridge elicited by addition of IPTG.

Our subsequent failure to elicit demonstrable DNA transfer to any of the strains of *C.*

sporogenes tested necessitated a substitution of the intended recombinant host with *C. acetobutylicum*. This clostridia has a number of advantages over *C. sporogenes*. On a practical level, we have already developed the necessary means of manipulating this species. Equally as important, this species has no known association with human disease and should therefore command a lower Access factor in any proposed recombinant experiments. The proposed expression of BoNT gene subfragments can therefore be undertaken at a lower category of containment. Furthermore, parallel studies undertaken in this laboratory have resulted in the construction of an expression cartridge, similar to that described above, based on the promoter of the ferredoxin (Fd) gene of *Clostridium pasteurianum*. This promoter, modified by the insertion of the *E. coli lac* operator, has been designated the *fac* promoter and shown to direct the expression of a *cat* gene in *C. acetobutylicum* NCIB 8052 to between 5 and 10% of the cells' soluble protein. Once *C. sporogenes* was abandoned as the recombinant host, efforts were therefore switched to attempting to obtain *lacI* expression in NCIB 8052.

4.2 Cloning of Botulinum Neurotoxin Genes:

The strategies utilised in the cloning of the type B, E, F and G neurotoxin genes were devised to minimise the risk of obtaining a toxinogenic *E. coli* recombinant clone, and mirrored the measures taken in the cloning of the BoNT/A gene, *botA* (Thompson et al., 1990). Thus, as both L and H chain are required for toxicity (Simpson, 1989), only DNA fragments encoding principally one component of the dichain were cloned. Where genomic fragments were cloned, their coding potential was determined by the construction of genomic maps using *botA* DNA probes in Southern blots. Furthermore, they were always isolated by two-stage agarose gel size fractionation to minimise the risk of cloning contiguous DNA fragments. As more nucleotide sequence information became available, specific regions were amplified for cloning by polymerase chain reaction (PCR).

BODY

1. CLONING OF THE BoNT GENES

1.1 MATERIALS AND METHODS

Bacterial strains, plasmids and culture conditions.

The source of chromosomal DNA was *C. botulinum* strain B/Danish, the type E strain NCTC 11219, the type F Langeland strain and the type G strain 89G. The recombinant host used for cloning experiments *E. coli* TG1 $\Delta[lac-pro]$ *supE thi hsdD5/ F'- traD36 proA⁺ E⁺ lacI^q lacZ Δ M15*). Cloning vectors employed were plasmids pMTL32 (this study), pMTL20 (Chambers et al., 1988), pCR1000 (Mead et al., 1991), and the M13 phages mp18 and mp19 (Yanisch-Perron, 1985). *C. botulinum* was cultivated in USA II broth (2% peptone, 1% yeast extract, 1% N-Z amine, 0.05% sodium mercaptoacetate, 1% glucose, pH 7.4), and *E. coli* in L-broth (1% tryptone, 0.5% yeast extract, 0.5% NaCl). Solidified medium (L-agar) consisted of L-broth with the addition of 2% (w/v) agar (Bacto.Difco). Antibiotic concentrations used for the maintenance and the selection of transformants were 50 μ g/ml ampicillin (pMTL32/pMTL20) and 50 μ g/ml kanamycin (pCR1000). Restriction endonucleases and DNA modifying enzymes were purchased from Northumbria Biochemicals Ltd, Taq polymerase from United States Biochemical Corporation and radiolabel from Amersham International.

Purification and manipulation of DNA.

Transformation of *E. coli* and large-scale plasmid isolation procedures were as previously described (Minton et al., 1983). Small-scale plasmid isolation was by the method of Holmes and Quigley (1981), while chromosomal DNA from *C. botulinum* was prepared essentially as described by Marmur (1961). Restriction endonucleases and DNA modifying enzymes were used under the conditions recommended by the supplier. Digests were electrophoresed in 1% agarose slab gels on a standard horizontal system (BRL Model H4), employing Tris-borate-EDTA (0.09 M Tris borate, 0.002 M EDTA) buffer. Fragments were isolated from gels using electroelution (McDonnell et al., 1977). All primary cloning procedures were undertaken under United Kingdom ACGM C2 containment conditions, and total cell lysates of all

recombinants carrying cloned material were tested in mice for the absence of toxic polypeptides.

DNA/DNA hybridisation experiments.

DNA restriction fragments were transferred from agarose gels to "zeta probe" nylon membrane using the procedure of Reed and Mann (1985). After partial depurination with 0.25 M HCL (15 min), DNA was transferred in 0.4 M NaOH by capillary elution for between 4 and 16 hours. Bacterial colonies were screened for desired recombinant plasmids by *in situ* colony hybridisation (Grunstein and Hogness, 1975), using nitrocellulose filter disks (Schleicher and Schull, 0.22 μ m). The gel purified *botA* DNA fragments were labelled with [α -³²P] dATP using a multiprime kit supplied by Amersham International. Hybridisations were carried out as previously described (Thompson et al., 1990), at temperatures ranging from 45 to 60 °C.

Nucleotide sequence of bot plasmid inserts.

The nucleotide sequences of plasmid inserts were determined by a number of different strategies. In some instances the entire insert was excised, circularised by treatment with T4 ligase and size fractionated 500-1000 bp fragments generated by sonication cloned into the *Sma*I site of M13mp18 (for experimental conditions, see Minton et al., 1986). Approximately 50 template were then sequenced by the dideoxynucleotide method of Sanger et al (1980) using a modified version of bacteriophage T7 DNA polymerase, "sequenase^R" (Tabor and Richardson, 1987). Experimental conditions used were as stated by the supplier (United States Biochemical Corp.). The inserts of other plasmid (eg., pCBB2 and pCBB3) were sequenced using templates derived by subcloning the entire region between the appropriate sites of M13mp18 and M13mp19. Sequence data obtained employing universal primer was then sequentially extended by the use of custom-synthesised oligonucleotide primers. In certain instances, templates were generated by the insertion of *Dra*I restriction subfragments into the *Sma*I site of M13mp18. In all cases the sequence was determined on both DNA strands. On some occasions PCR amplified DNA was cloned directly into either pCR1000 or ddT-tailed, *Sma*I cut M13mp8 (prepared by incubating *Sma*I cut DNA with terminal transferase in the presence of dideoxy TTP), and the resultant plasmid/ template sequenced with universal primer. DNA sequence data was analysed using the computer software of DNASTAR Inc.

Amplification of DNA by PCR.

Amplification of *C. botulinum* DNA was undertaken by polymerase chain reaction (PCR), using an M J Research Inc. Thermal cycler. Reaction mixtures comprised, 10 mM Tris-HCl, 50 mM KCl, 3 mM MgCl₂, 0.1 mM dNTP, 30 nmol of each primer, 2.5 units of Taq polymerase, and 10 ng of *C. botulinum* genomic DNA, in a final volume of 0.1 ml. Amplification was for 30 cycles, as follows: 1.5 min at 93°C; 3 min at 37°, and; 3 min at 72°C. For inverse PCR, 140 ng of chromosomal DNA, cleaved with an appropriate restriction endonuclease, was ligated overnight at 14°C in a 50 µl volume and a 10 µl portion of the resultant concatenated DNA used in PCR.

1.2 CLONING/ SEQUENCING OF THE BoNT/E GENE

1.2.1 Summary

The entire structural gene of the *Clostridium botulinum* NCTC 11219 type E neurotoxin gene has been cloned as 5 overlapping DNA fragments, generated by PCR. Analysis of triplicate clones of each fragment, derived from 3 independent PCR's, has allowed the derivation of the entire nucleotide sequence of the BoNT/E gene. Translation of the sequence has shown BoNT/E to consist of 1252 amino acids, and as such represents the smallest BoNT characterised to date. The L chain of the toxin exhibits the highest level of sequence similarity to TeTx (40%). The L chains of BoNT/A and BoNT/D share 33% similarity with BoNT/E, while BoNT/C exhibits 32% similarity. In contrast, the TeTx H chain exhibits the lowest degree of homology (35%) with BoNT/E, with the BoNT H chains sharing 46%, 36% and 37%, for the type A, C and D neurotoxin types, respectively. Comparisons with partial amino acid sequences of the L chain of BoNT/E from *C. botulinum* strain Beluga and that from the strains Mashike, Iwanai and Otaru, indicate single amino acid differences in each case. Alignment of all characterised neurotoxins sequences (BoNT/A, BoNT/C, BoNT/D, BoNT/E and TeTx) shows them to be composed of highly conserved amino acid domains interspersed with amino acid tracts exhibiting little overall similarity. The most divergent region corresponds to the extreme C-terminus of each toxin, which may reflect differences in specificity of binding to neurone acceptor sites.

1.2.2 Results and Discussion

Probing with type A neurotoxin gene subfragments

To identify specific restriction fragments encoding principally L or H chain we initially sought to exploit DNA homology between the previously cloned BoNT/A gene (Thompson et al., 1990) and the BoNT/E gene. Two restriction fragments were gel-purified from the BoNT/A gene. The first, a 389 bp *HpaI-XhoII* fragment, encoded amino acids 216 through 346 of the BoNT/A L chain. The second, a 628 bp *HaeIII-HindIII* fragment, coded for amino acids 526 through 736 of the H chain (Thompson et al., 1990). Both fragments were radiolabelled and used in Southern blot experiments, employing type E genomic DNA cleaved with various restriction enzymes. Under aqueous conditions, it was established that hybridisation between the two genes occurred at 50°C in the case of the L chain probe, and at 53°C in the case of the H chain probe. The relatively low value of these figures was indicative of a fairly low level of homology between the genes in the regions probed, and, furthermore, suggested that homology was greater in the H chain encoding region.

Further experiments, in which the genomic DNA hybridised had been cleaved with a combination of endonucleases, allowed the derivation of crude restriction maps of the regions of the type E genome homologous to the type A probes employed (data not shown). Inexplicably, the two sets of results obtained could not be merged into a single unifying restriction map. This anomaly in the derived data meant that the coding potential of any particular fragment, with regard to the BoNT/E gene, could not be confidently assigned. A different route to cloning was therefore adopted.

Cloning of the L chain encoding region by PCR

By reference to published amino acid sequences of the NH₂-terminus of the BoNT/E H and L chains (Sathyamoorthy and Dasgupta, 1985; Schmidt et al., 1985), two oligonucleotides were synthesised (primers LE1 and HE1, Table 1) which would allow amplification of essentially the entire L chain encoding region by polymerase chain reaction (PCR). The nucleotides in positions of codon degeneracy were chosen on the basis of those most commonly found in clostridial genes (Young et al., 1989). PCR was undertaken with LE1 and HE1 and type E chromosomal DNA, at various temperatures, in buffer containing Mg²⁺ at final concentrations of either, 1.5, 2.2 or 3.0 mM. Agarose gel electrophoresis of the reaction products indicated that no specific DNA fragment had been generated. Previous comparative alignment of the BoNT/A and TeTx L chains (Thompson et al., 1990) had indicated that very few amino acids were absolutely conserved. One notable exception was a centrally located histidine rich motif. Indeed a preliminary amino acid sequence of part of the BoNT/E L chain confirmed that this motif was also present in BoNT/E (Wernars and Notermans, 1990). Two

Table 1. *Synthesised oligonucleotide primers employed in PCR-amplification of Clostridium botulinum NCTC 11219 genomic DNA.*

OLIGO	ABILITY TO PRIME	NUCLEOTIDE SEQUENCE ^a	NUCLEOTIDE POSITION ^b IN BoNT/E GENE	AMINO ACID ^c POSITION	REFERENCE
LE1	NO	I N S F N Y N D P 5'-ATAAATAGTTTAAATTATAAAGATCC-3' T T	237-262	BoNT/E, 4-12	Sathyamoorthy et al. (1985)
LE2	YES	H E L I H S L H G 5'-CACGAACCTTATACATTCTCTACATGG-3' T A A T	861-886	BoNT/E, 212-220	Wernars & Notermans (1990)
LE2'	YES	H E L I H S L H G 3'-GTGCTTGAATATGTAAGAGATGTACC-5' A A T T A	886-861	BoNT/E, 212-220	"
LE3	YES	F N Y N D P V N D 5'-TTTAAATATAATGATCCTGTAAATGA-3' T	246-271	BoNT/E, 7-15	Sathyamoorthy et al. (1985)
HE1	YES	I C I E I N M G E 3'-TATACATATCTTTATTATTACCTCT-5' G A	1525-1501	BoNT/E _H , 3-11	"
HE2	YES	P Y I G P A L N I 5'-CCATATATAGGACCGACATTAAATAT-3' T T T	2037-2062	BoNT/A, 635-643	Thompson et al. (1990)
HE3	YES	K R N E K W D E V 5'-AAAAGAAATGAAAAATGGGATGAAGT-3' G G C A	2244-2269	BoNT/A, 701-709	"
HE4	YES	N K A M I N I M K F 5'-AATAAGCAATGATAAATATAAATAAATT-3' T C T A T G C G G	2481-2509	BoNT/A, 778-887	"
HE5	YES	N R W I F V T I T N 3'-TTATCTACCTATAAACATGTATTGTTT-5' T C A A A	3129-3217	BoNT/A, 1012-1021	"
HE6	NO	G T K F L I K K Y 3'-CCTTGTTTAAATATTATTTTAT-5' A C T G C C A	3597-3622	BoNT/A, 1157-1165	"
HE7	NO	W E F I P V D D G W 3'-ACCCTTAAATATGGTCATCTACTTCCAACC-5' T G A A A T G A T	3945-3974	BoNT/A, 1272-1291	"
LE4	YES	C R Q T V I G Q Y 5'-GTAGGCAAACTTATATTGGACAGTA-3'	1267-1291	BoNT/E, 347-355	this study
HE8	YES	I V S N W M T K 3'-TATCATAGCTTAACCTACTGATT-5'	2280-2303	BoNT/E, 685-692	this study
LE5	YES	T P D M Q F M I 3'-TGAGGTCTATTAGTTAAGGTATAAC-5'	582-606	BoNT/E, 119-126	this study
LE6	YES	L I T W I R G T 5'-CTAATAACAAATATAAGAGGTAC-3'	945-967	BoNT/E, 240-247	this study
HE9	YES	K M F S I S F W V R 3'-TTTTAAATCATAATCAAAGACCCATTC-5' A	2965-2992	BoNT/E, 913-921	this study
HE10	YES	D N M S G W K V 5'-ATAATAATTCAGGATGGAAGTAT-3'	3041-3084	BoNT/E, 945-952	this study

^a the oligonucleotide primers LE1-LE3 and HE1-HE7 are "guessomers", designed to prime/anneal to DNA sequence encoding the amino sequence illustrated above. These amino sequences were either derived by NH₂-terminal sequencing of purified BoNT/E light- and heavy-chain subunits, or from the BoNT/A sequence, previously determined by recombinant means [Thompson et al., 1990]. Where these primers differed from the actual DNA sequence of the BoNT/E gene is illustrated below the sequence. With the exception of LE9, all other primers are perfect primers, based on the determined BoNT/E gene sequence. Primer LE9 is based on the equivalent region of the BoNT/F gene, which differs from the BoNT/E gene in this region by one nucleotide (unpublished data).

^b position in the BoNT/E gene to which the oligonucleotides are targeted. Numbers correspond to nucleotide positions in Fig.2.

^c numbering corresponds to the position of the amino acid sequence illustrated above the oligonucleotide.

further primers (LE2 and LE2', Table 1) were therefore synthesised corresponding to the sense and anti-sense DNA strand capable of encoding the histidine rich motif of the BoNT/E L chain. Subsequent PCR, at an annealing temperature of 37°C, using the primer pairs LE1 + LE2', and LE2 + HE1, resulted in a amplified DNA fragment of the expected size only in the case of the latter pair. Furthermore, appreciable amounts of DNA were only generated at the highest Mg^{2+} concentrations employed. These data suggested that the failure of the initial PCR to amplify a specific DNA fragment was due to inefficient priming of LE1. An alternative primer was therefore synthesised (LE3, Table 1), and used in combination with HE1 in a further PCR assay. In this case a DNA fragment of the expected size, 1.3 kb, was evident, following subsequent agarose gel electrophoresis of the reaction products.

The amplified products of the LE3 + HE1 reaction were blunt-ended with T4 polymerase and cloned into the *Sma*I site of pMTL20. Restriction analysis of 6 resultant recombinant plasmids indicated the presence of a common restriction fragment. Confirmation that the amplified fragment encoded BoNT/E was obtained by plasmid sequencing a representative plasmid recombinant (designated pCBE1) with both universal and reverse primer. Translation of the derived DNA sequences resulted in an uninterrupted amino acid sequence, which in the case of that derived using universal primer exhibited 100% identity with a preliminary BoNT/E sequence (Wernars and Notermans, 1990), while the sequence derived using reverse primer had substantial homology to the COOH-terminus of the BoNT/A L chain. Having established that the amplified fragment encoded BoNT/E, the entire nucleotide sequence of the pCBE1 insert was determined, as described in MATERIALS AND METHODS.

Cloning of H chain encoding DNA by PCR

In parallel to the experiments described above, a number of oligonucleotides were synthesised with a view to amplifying DNA regions of the neurotoxin gene encoding parts of the H chain. In the absence of amino acid sequence data for the BoNT/E H chain, we reasoned that amino acid motifs common to BoNT/A and TeTx may also be present in BoNT/E. The synthesised oligonucleotides (Table 1) therefore corresponded to a sense or anti-sense DNA strand capable of encoding amino acid motifs found in BoNT/A which were highly conserved in TeTx (Thompson et al., 1990). Individual PCR's were undertaken with all possible combinations of the sense and anti-sense oligonucleotides, under the conditions successfully established with the L chain primers. The only pairs of primers found to generate DNA fragments of the expected size were HE2 + HE5, HE3 + HE5, and HE4 + HE5. As the fragment derived from the reaction involving HE2 + HE5 was the largest (c. 1.2 kb), this particular DNA product was cloned, following blunt-ending, into the *Sma*I site of pMTL20. Plasmid sequencing of the resultant recombinant, pCBE2, and translation of the nucleotide

sequence obtained established the presence of uninterrupted amino acid sequences exhibiting significant homology to the BoNT/A H chain. Thereafter, the complete nucleotide sequence of the insert of pCBE2 was determined (see MATERIALS AND METHODS).




Fig. 1. *BoNT/E* gene cloning strategy. The 5 PCR-amplified regions of NCTC 11219 chromosome, that were cloned in the recombinant plasmids pCBE1-5, are represented by open boxes below the restriction map of the region of the genome encoding the *BoNT/E* gene. LE and HE primer sequences are given in Table 1. The arrows indicate the direction of DNA synthesis; solid arrows are perfect primers, open arrows guessomers. The vertical dotted line identifies the boundaries of the concatenated restriction fragment employed as the substrate for inverse PCR, using primer pairs LE5 + LE6 and LE9 + LE10.

Cloning of the remainder of the BoNT/E gene

To clone the intervening *BoNT/E* DNA between the inserts of pCBE1 and pCBE2, two oligonucleotides primers (LE4 and HE8; Table 1) were synthesised based on the determined nucleotide sequences of the pCBE1/2 inserts. The 1.03 kb product generated in a PCR using these primers was cloned directly into the specialised cloning vector pCR1000, and the nucleotide sequences of the inserts of a representative clone, pCBE3, determined.

DNA fragments carrying the remaining 3' and 5' ends of the *BoNT/E* gene were generated

by inverse PCR. This strategy required the identification of restriction sites proximal and distal to the gene. These sites were mapped by employing the radiolabelled PCR products generated by LE2 + H1 and HE2 + HE5, in Southern blot experiments with restricted type E chromosomal DNA. The data obtained, together with information available from the nucleotide sequences of the inserts of pCBE1 and pCBE2, was used to construct an accurate restriction map of the region of the type E genome encoding the BoNT/E gene (Figure 1). This indicated that the 5' end of the structural gene resided on a c 1.0 kb *EcoRI* fragment, and that the 3' end of the gene was encompassed by a 1.1 kb *DdeI* fragment. Accordingly, type E chromosomal DNA was cleaved with the appropriate enzyme, self-ligated and a PCR undertaken on the circularised products using the oligonucleotide primer pairs LE5 + LE6 in the case of *EcoRI* cleaved DNA, and HE9 + HE10 in the case of DNA cut with *DdeI*. In both cases, DNA fragments of the calculated size were shown to be generated. Each amplified DNA product was cloned directly into pCR1000 (Mead et al., 1991), yielding pCBE4 (3'-end) and pCBE5 (5'-end), and the entire nucleotide sequences of their inserts determined (MATERIALS AND METHODS).

The complete nucleotide sequence of the BoNT/E gene

The 5 overlapping nucleotide sequences derived from the inserts of pCBE1 to pCBE5 in total encompassed the entire BoNT/E structural gene. However, because Taq polymerase is known to misincorporate nucleotides during DNA synthesis (Eckert and Kunkel, 1991), the sequence obtained may not have represented the authentic BoNT/E sequence. Therefore, all 5 cloned DNA fragments were reamplified by PCR, and cloned to give duplicate isolates of the five plasmids, pCBE1 to pCBE5. The nucleotide sequences of the entire inserts of each new plasmid were determined and compared to that derived from the initial clones. In those cases where a discrepancy in sequence was apparent, the appropriate fragment was PCR-amplified and cloned to give a third pCBE clone. The relevant region of the insert of this plasmid was then determined, and the consensus of the 3 sequences taken as being the correct BoNT/E gene sequence. The number of discrepancies in the three sequences was surprisingly high, with a total of 7 PCR-induced substitutions and 2 single base additions. Both of the latter, occurred in regions of the sequence composed of at least 5 consecutive 'A' nucleotides. This error rate equates to 7.8×10^{-4} per nt (ie., 9 errors per 11500 bases) and is most probably a direct result of the relatively high level of Mg^{2+} employed (Eckert and Kunkel, 1991).

The final sequence derived is illustrated in Fig. 2. The BoNT/E gene has a 75% A+T content and is composed of 1253 codons, initiating at nucleotide position 228 with a AUG codon and terminating at position 3986 with a UAA stop codon. The use of these particular translational initiation and termination signals is a general characteristic of clostridial genes

EcoRI
GAATTCAACTAGTAGATAATAAAAAATATCCACAGATTTTATTATTAATAATGATATTTTATCTCTAACTGTTTAACTTTAACTTATAACAATGTAAA 100
-10 9 +1 Tc
TGTATATTGTCTATAAAAAATCAAGATTACAATTGGGTTATATGTGATCTTAATCATGATATACCAAAAAAGTCATATCTATGGATATTAATAATATA 200
8
M P K I N S F N Y W D P V N J R T I L Y I K P G
TAAATTTAAAAATAGGAGATGCTGTATATGCCAAAAATTAATAGTTTAAATTATAATGATCCTGTTAATGATAGAACAAATTTTATAATTAAACAGGCG 300
G C Q E F Y K S F N I M K N I W I I P E R N V I L T T P Q D F H P P
GTTGTCAAGAATTTTATAAATCATTAAATATTGAAAAATATTGGATAATTCAGAGAGAAATGTAATTGGTACAAACCCCAAGATTTTCATCCGCC 400
T S L K N G D S S Y Y D P N Y L Q S D E E K D R F L K I V T K I F
TACTTCATTAATAAATGGAGATAGTAGTTATTATGACCCCTAATTATTACAAAGTGATGAAGAAAGGATAGATTTTAAAAATAGTCACAAAAATATTT 500
N R I N M N L S G G I L L E E L S K A N P Y L G N D N T P D N Q F
AATAGAATAAATAAATCTTTCAGGAGGGATTTTATTAGAAGAACTGCAAAAGCTAATCCATATTAGGGAATGATAATACTCCAGATAATCAATTC 600
N I G D A S A V E I K F S N G S Q D I L L P M V I I M G A E P D L F
ATATTGGTGATGCATCAGCAGTTGAGATTAATTTCTCAAATGGTACCAAGACATATTACCTAATGTTATTATAATGGGAGCAGAGCCTGATTTATT 700
E T M S S L I S L R N N Y M P S N H G F G S I A I V T F S P E Y S
TGAACTAACAGTTCCAATATTTCTCTAAGAAATAATTATATGCCAAGCAATCACGGTTTGGATCAATAGCTATAGTAACATTCTCACCTGAATTTCT 800
F R F N D N S M N E F I Q D P A L T L M H E L I H S L H G L Y G A
TTTAGATTTAATGATAATAGTAGTGAATGAATTTATTCAAGATCTGCTCTTACATTAATGCATGAATTAATACATTCAATACATGGACTATATGGGGCTA 900
K G I T T K Y T I T Q K Q M P L I T M I R G T N I E E F L T F G G T
AAGGGATTACTACAAAGTATACTATAACACAAAAACAAATCCCTAATAACAAATATAAGAGGTACAAATATTGAAGAAATCTTAACTTTTGGAGGTAC 1000
D L N I I T S A Q S N D I Y T N L L A D Y K K I A S K L S K V Q V
TGATTTAAACATTATTACTAGTGCTCAGTCCAATGATATCTATACTAATCTTCTAGCTGATTAATAAAAAATAGCGTCTAACTTAGCAAGTACAAGTA 1100
S M P L L N P Y K D V F E A K Y G L D K D A S S I Y S V N I N K F
TCTAATCCACTACTTAATCCTTATAAGATGTTTTGAAGCAAAGTATGGATTAGATAAAGATGCTAGCCAAATTTATTCGGTAAATAAACAATTTA 1200
N D I F K K L Y S F T E F D L A T K F Q V K C R Q T Y I G Q Y K Y F
ATGATATTTTAAAAAATATACAGCTTTACGGAATTTGATTTAGCACTAAATTTCAAGTTAAATGTAGGCAAACTTATATGGACAGTATAAATACTT 1300
K L S N L L N D S I Y N I S E G Y N I N N L K V N F R G G N A N L
CAAACTTTCAAACCTGTTAAATGATTCTATTATAATATATCAGAAAGGCTAATAATAAATTTAAAGGTAAATTTAGAGGACAGAAATGCAAAATTTA 1400
M P R I I T P I T G R G L V K K I I R F C K N I V S V K G I R K S
AATCCTAGAATTATTACACCAATTACAGGTAGAGGACTAGTAAAAAATCTTATAGATTTTGTAAAAATATTGTTTCTGTAAAGGCTAAGGAAATCAA 1500
I C I E I N M G E L F F V A S E N S Y N D D N I N T P K E I D D T V
TATGTATCGAAATAAATAATGGTGAGTTATTTTTGTGGCTTCGAGAAATAGTTATAATGATGATAATATAAATACTCTAAAGAAATTGACGATACAGT 1600
T S N N N Y E N D L D Q V I L N F N S E S A P G L S D E K L N L T
AACCTTCAAATAAATATTGAAATGATTAGTTCAGGTTATTTAAATTTTAAATAGTGAATCAGCACCTGGACTTTGAGATGAAAAATTAATTTAACT 1700
I Q N D A Y I P K Y D S N G T S D I E Q H D V N E L N V F F Y L D
ATCCAAATGATGCTTATATACCAAAATGATTCTAATGGAACAAGTGATATAGAACAACATGATGTTAATGAACCTAATGATTTTTCTATTAGATG 1800
A Q K V P E G E N N V N L T S S I D T A L L E Q P K I Y T F F S S E
CACAGAAAGTGCCGAAGGTAAAAATAATGTCAATCTCACCTCTTCAATTGATACAGCATTATTAGAACAACCTAAAAATATATACATTTTTTTCATCAGA 1900
F I N N V N K P V Q A A L F V S W I Q Q V L V D F T T E A N Q K S
ATTTATTAATAATGTCAATAAACCTGTGCAAGCAGCATTATTGTAAAGCTGGATACACAAGTGTTAGTAGATTTTACTACTGAAGCTAACCAAAAAAGT 2000
T V D K I A D I S I V V P Y I G L A L N I G N E A Q K G N F K D A
ACTGTTGATAAAATTCGAGATATTTCTATAGTGTTCATATATAGGTCTTGGCTTTAAATATAGGAAATGAAGCACAAAAAGGAAATTTTAAAGATGCAC 2100
L E L L G A G I L L E F E P E L L I P T I L V F T I K S F L G S S D
TTGAATATTAGGAGCAGGTATTTTATTAGAATTTGAACCCGAGCTTTTAAATCTCAATTTTAGTATTACGATAAAATCTTTTATAGTTTCATCTGA 2200
M K N K V I K A I N N A L K E R D E K W K E V Y S F I V S N W M T
TAATAAAAAATAAGTTATTAAAGCAATAAATAATGCATTGAAAGAAAGAGATGAAAAATGGAAGAAAGTATATAGTTTATAGTATCGAATTGGATGACT 2300

Fig 2. Complete nucleotide sequence of the type E gene. The BoNT/E amino acid sequence is given in the single letter code above the central nucleotide of the corresponding codon. Differences between the NCTC 11219 sequence and the partial nucleotide sequences of the genes of strain Beluga and

K I N T O F N K R K E O M Y O A L Q N Q V M A I K T I I E S K Y M
 AAAATTAATACACAAATTTAATAAAAGAAAAGACAAATGTATCAAGCTTTACAAAATCAAGTAAATGCAATTAACAAATAATAGAATCTAAGTATAATA 2400
 S Y T L E E K N E L T N K Y D I K Q I E N E L N Q K V S I A M N N I
 GTTATACCTTAGAGGAAAAAATGAGCTTACAAATAAATATGATATTAAAGCAATAGAAAATGAACTTAATCAAAGGTTTCTATAGCAATGAATAATAT 2500
 D R F L T E S S I S Y L M K L I N E V K I N K L R E Y D E N V K T
 AGACAGGTTCTTAAGTAAAGTTCTATATCTATTTAATGAAATTAATAATGAAGTAAATTAATAATTAAGAGAAATGATGAGAAATGCAAAACG 2600
 Y L L N Y I I Q H G S I L G E S Q Q E L N S M V T D T L N N S I P
 TATTTATTGAATTATATTATACACATGGATCAATCTTGGGAGAGAGTCAGCAAGAACTAAATTTCTATGGTAACTGATACCCATAATAATAGTATTCCTT 2700
 F K L S S Y T D D K I L I S Y F N K F F K R I K S S S V L N M R Y K
 TTAAGCTTTCTTATACAGATGATAAAATTTAATTTTCATATTTTATAAATTTCTTTAAGAGAAATTAAGTAGTTTCAAGTTTAAATATGAGATATAA 2800
 M D K Y V D T S G Y D S N I N I N G D V Y K Y P T N K N Q F G I Y
 AAATGATAAATACGTAGATCTTCAAGATATGATTCAATATATAATATTAATGGAGATGTATATAATATCCAATAATAAAATCAATTTGGAATATAT 2900
 N D K L S E V N I S Q N D Y I I Y D N K Y K N F S I S F W V R I P
 AATGATAAACTTAGTGAAGTTAATATATCTCAAAATGATTACATTATATGATAATAATAATAAAATTTTAGTATTAGTTTGGGTAAGAAATTCCTA 3000
 N Y D N K I V N V N H E Y T I I N C M R D N N S G W K V S L M H M E
 ACTATGATAATAAGATAGTAAATGTTAATAATGAATACACTATAATAAATGATGAGAGATAATAATTCAGGATGGAAAGTATCTCTTAATCATATGA 3100
 I I W T L Q D N A G I N Q K L A F N Y G N A N G I S D Y I N K W I
 AATAATTTGGACATTGCAAGATAATGCAGGAATTAATCAAAAATTAGCATTAACTATGGTAACGCAATGGTATTCTGATTATATAATAAGTGGATT 3200
 F V T I T M D R L G D S K L Y I N G N L I D Q K S I L N L G N I N
 TTTGTAACATACTAATGATAGATTAGGAGATTCTAACTTTATATTAATGGAAATTTAATAGATCAAAAATCAATTTTAAATTTAGGTAATATTCATG 3300
 V S D N I L F K I V M C S Y T R Y I G I R Y F N I F D K E L D E T E
 TTAGTGACAAATATATTTTAAATAGTTAATTTGAGTTATACAAGATATATTGGTATTAGATATTTAATATTTTGATAAAGAAATAGATGAAACAGA 3400
 I Q T L Y S N E P N T N I L K D F W G M Y L L Y D K E Y Y L L N V
 AATTCAAACCTTTATATAGCAATGAACCTAATACAAATATTTTGAAGGATTTTGGGAAATTAATTTGCTTTATGACAAAGAACTACTATTTATTAATAGTG 3500
 L K P N M F I D R R K D S T L S I N W I R S T I L L A N R L Y S G
 TTAACCAAAATAACTTTATTGATAGAGAGAAAGATTCTACTTTAAGCATTAAATATAAGAGCACTATTCTTTAGCTAATAGATTATATAGTGGAA 3600
 I K V K I Q R V M N S S T M D N L V R K N D Q V Y I N F V A S K T H
 TAAAGTAAATAACAAAGAGTTAATAATAGTAGTACTAAGCATAATCTTGTAGAGAAAGATGATCAGGTATATATTAATTTGTAGCCAGCAAACTCA 3700
 L F P L Y A D T A T T N K E K T I K I S S S G N R F N Q V V V M N
 CTTATTTCCATTATATGCTGATACAGCTACCACAAATAAGAGAGAAACAAATAAAATATCATCATCTGGCAATAGATTTAATCAAGTAGTAGTTATGAAT 3800
 S V G M N C T M N F K N N G N N I G L L G F K A D T V V A S T W
 TCAGTAGGAAATAATTGTACAAATGAATTTTAAATAATAATGGTAATAATATTGGGTGTTAGGTTTCAAGGCAGACTGTAGTTGCTAGTACTTGGT 3900
 Y Y T H M R D N T N S N G C F W N F I S E E N G W Q E K
 ATTATACATATGAGAGATCATACAAACAGCAATGGATGTTTTTGGAACTTTATTTCTGAAGAACATGGATGGCAAGAAAAATAAAATTAGATTAAC 4000
 GGCTAAAGTCATAAATCCAAGGACTTAG 4030
 DdeI

strains Mashike, Iwanai and Otaru, are indicated below the appropriate position of the sequence, in lower and upper case letters, respectively. An upward facing arrow indicates an insertion. Any change in the encoded amino acid is indicated above the NCTC BoNT/E amino acid sequence. The putative -10 promoter region (based on homology to the BoNT/A gene 5' non-coding region) and transcriptional initiation site are marked by a dashed line above the sequence and downward facing arrow, respectively. The ribosome binding site is indicated by a line above and below the sequence.

(Young et al., 1989). The AUG codon is preceded by a sequence typical of clostridial ribosome binding sites, in both its composition and distance (8 bases) from the AUG initiation codon. The codon usage exhibited by the gene is also typical of clostridial genes, with an extreme bias for codons ending in A and T, and the frequent use of codons recognised as

modulators of translation in *E. coli*. Although a number of sequences 5' to the BoNT/E structural gene exhibit some similarity to procaryotic promoter elements, assignment of such sequences as transcriptional signals will require appropriate experimental data. A reasonably high degree of sequence similarity (77.4% identity) does, however, exist between the 5' non-coding region of the BoNT/A (Binz et al., 1990) and BoNT/E gene. Based on this homology, the transcriptional start point would be nucleotide 117, and the TATATT motif at position 103 to 108 the putative -10 promoter element (Figure 2).

The sequence of a 983 bp portion of the BoNT/E gene (equivalent to nucleotides 1 to 988 of Fig. 2), encoding part of the L chain, from a number of other *C. botulinum* type E strains has been reported, namely strain Beluga (Binz et al., 1990) and strains Mashike, Iwanai and Otaru (Fujii et al., 1990). The sequences derived from the latter 3 strains were identical and differ from that reported here for strain NCTC 11219 by a single nucleotide at position 916. Thus codon 230 of the BoNT/E genes from strains Mashike, Iwanai and Otaru is UAG, while in the BoNT/E gene of strain NCTC 11219, this codon is AAG. In contrast, the sequence derived from strain Beluga exhibits 4 nucleotide differences to the sequence of NCTC 11219. Three of these changes occur in the 5' non-coding region, including a single base 'C' insertion in the Beluga sequence (see Fig. 2), while the fourth difference results in a codon alteration of CGT (Beluga) to GGT (NCTC 11219) at position 756 (Fig. 2).

Comparative alignment of the nucleotide sequence of the two regions of the BoNT/A gene used as DNA probes in our original experiments, to the equivalent region of the BoNT/E gene, confirmed that a greater degree of DNA homology occurred between the H chain probe than the L chain probe. Thus, the 389 bp BoNT/A *HpaI*-*XhoII* fragment exhibited 61.7% homology to the BoNT/E gene, whereas the 628 bp *HaeIII*-*HindIII* fragment demonstrated 67.3% homology with the BoNT/E gene. The attainment of the complete nucleotide sequence of the BoNT/E gene also provided an opportunity to assess the reasons for the apparent ability/inability of the synthesised oligonucleotides to act as primers in PCR (Table 1). Such an assessment did not prove particularly informative. Thus, although the presence of 7 sequence mismatches in the case of HE6 may have precluded annealing to BoNT/E genomic DNA, 9 sequence mismatches in oligonucleotide HE4 apparently did not effect its ability to prime in PCR, assuming the generated fragment was indeed the region targeted. The success of primer HE4 may have been due to the fact that the 4 mismatches at the 3' end of the oligonucleotide would all have resulted in neutral d(G-T) pairing. More difficult to explain was the inability of LE1 to act as a primer (only 2 mismatches).

The complete amino acid sequence of the BoNT/E gene

The deduced amino acid sequence of BoNT/E demonstrated that the neurotoxin is comprised of 1252 residues, making it the smallest neurotoxin yet characterised. The amino acids at positions 423 through 435 demonstrated perfect agreement with those determined experimentally by NH₂-terminal sequencing of the purified BoNT/E H chain (Sathyamoorthy and Dasgupta, 1985; Schmidt et al., 1985). A more extensive recent sequence had indicated a presence of a single unassigned amino acid ("X") at BoNT/E_H positions 16 and 19 (Dasgupta and Datta, 1988). The sequence deduced here indicates that the first "X" equates to the dipeptide sequence Ala-Ser, while the second "X" is a Ser residue. Comparisons between the NCTC 11219 L chain and the partial amino acid sequences of the BoNT/E L chains of strain Beluga and strains Mashike, Iwanai and Otaru, indicated a single amino acid difference in each case. Thus, the Gly residue at position 177 in the NCTC 11219 toxin has been replaced by Arg in Beluga BoNT/E, while the Lys amino acid at position 230 in the NCTC 11219 BoNT/E is Met in the equivalent position of the three Japanese strain-derived toxins.

1.3 CLONING/ SEQUENCING OF THE BoNT/B GENE

1.3.1 Summary

DNA fragments derived from the *Clostridium botulinum* type A neurotoxin (BoNT/A) gene (*botA*) were used in DNA/DNA hybridisation reactions to derive a restriction map of the region of the *C. botulinum* type B strain Danish chromosome encoding *botB*. As the one probe encoded part of the BoNT/A heavy (H) chain, and the other part of the light (L) chain, the position and orientation of *botB* relative to this map was established. The temperature at which hybridisation occurred indicated that a higher degree of DNA homology occurred between the two genes in the H chain encoding region. Using the derived restriction map data, a 2.1 kb *Bgl*III-*Xba*I fragment encoding the entire BoNT/B L chain and 108 amino acids of the H chain was cloned and characterised by nucleotide sequencing. A contiguous 1.8 kb *Xba*I fragment encoding a further 623 amino acids of the H chain was also cloned. The 3'-end of the gene was obtained by cloning a 1.6 kb fragment amplified from genomic DNA by inverse polymerase chain reaction. Translation of the nucleotide sequence derived from all three clones demonstrated that BoNT/B was composed of 1291 amino acids. Comparative alignment of its sequence with all currently characterised BoNT's (A, C, D, E) and tetanus (TeTx) showed that a wide variation in percentage homology occurred dependent on which component of the dichain was compared. Thus, the L chain of BoNT/B exhibits the greatest degree of

homology (50% identity) with the TeTx L chain, whereas it's H chain is most homologous (48% identity) with the BoNT/A H chain. Overall, the 6 neurotoxins were shown to be composed of highly conserved amino acid domains interceded with amino acid tracts exhibiting little overall similarity. In total 68 amino acids, out of an average of 442, are absolutely conserved between L chains and 110, out of 845 amino acids, between H chains. Conservation of Trp residues (1 in the L chain, and 9 in the H chain) was particularly striking. The most divergent region corresponds to the extreme carboxyterminus of each toxin, which may reflect differences in specificity of binding to neurone acceptor sites.

1.3.2 Results and Discussion

Southern blot analysis of the botB gene

A 389 bp *HpaI-XhoII botA* fragment, encoding amino acids 216 through 346 of the BoNT/A L chain, and a 628 bp *HaeII-HindIII* fragment, coding for amino acids 526 through 736 of the H chain (Thompson et al., 1990), were radiolabelled and used in DNA/DNA hybridisations with type B chromosomal DNA cleaved with various restriction enzymes. Reactions were performed in aqueous solution over a range of temperatures. "Weak" hybridisation between the two genes was found to occur at 53°C and 56°C with the L and H chain probes, respectively (data not shown). The strength of the signal observed, and the relatively low stringency required were indicative of a fairly low level of DNA homology between *botA* and *botB*. Furthermore, these results suggest that the L chain encoding regions of the two genes are less homologous than the H chain encoding region, at least in the areas probed. Having established the conditions at which hybridisation occurred, the type B genomic DNA was cleaved with various combinations of restriction endonucleases and the nylon membranes carrying the resultant fragments sequentially hybridised with the two probes. The data obtained allowed the derivation of a restriction map of the region of the type B genome encoding *botB*. Furthermore the use of the two probes enabled the assignment of both the position of *botB* and its relative orientation, with respect to the derived map (Fig. 3).

Cloning and sequencing of the botB L chain.

The restriction map derived by the Southern blot experiments (Fig. 3) indicated that a 2.1 kb *BglII-XbaI* fragment principally encoded the L chain of BoNT/B. To clone this DNA, and to minimise the risk of cloning contiguous BoNT/B encoding regions, the targeted fragment was purified by a two-stage gel isolation procedure. *C. botulinum* type B chromosomal DNA

was cleaved with *Xba*I and fragments of approximately 7.5 kb in size purified from agarose gels by electroelution. The isolated DNA was then subjected to digestion with *Bgl*III, DNA fragments of around 2.1 kb in size gel-purified, ligated to similarly cut pMTL32 vector DNA




Fig. 3. Strategy employed in the cloning of the *botB* gene. The illustrated restriction map of the *C. botulinum* genome was generated using the indicated *botA* DNA fragments as probes in Southern blots. Regions of the strain B/Danish chromosome, that were cloned in the recombinant plasmids pCBB1 and pCBB2, are represented by open boxes below the restriction map. The cloned inserts of these plasmids were shown to be contiguous on the genome by PCR amplification of the region of the chromosome spanning their common *Xba*I site, using primers X1 (5'-CCAAGTGAAAATACAGAATCAC-3') and X2 (3'-CCCACTTTGTCTATCATTTA-5'), and sequencing across this junction. The insert of pCBB3 was derived by PCR amplification of *Hind*III cut, concatenated chromosomal DNA using primers X4 (5'-AT-AGAGATTATATATTGGAG-3') and X3 (5'-TTATATACAGCCAAATGCTCCTTGC-3')

(Fig. 4), and the resultant TC1 transformants screened for the presence of recombinant clones using the *botA* L chain probe. The vector pMTL32 was specifically constructed for the purposes of cloning the *botB* DNA (see Fig. 4). Based on the pMTL1003 backbone (Brehm et al., 1991), it carries multiple cloning sites flanked on either side by tandem copies of transcriptional terminators. Heterologous genes inserted into the multiple cloning sites will therefore only be expressed if they carry indigenous transcriptional elements recognised by the RNA polymerases of *E. coli*.




Fig. 4. The cloning vector *pMTL32*. This plasmid was derived as follows. A synthetic DNA fragment (5'-AGCCCGCCTAATGAGCGGGCTTTTTT-3'), corresponding to the *E. coli trpA* transcriptional terminator, was ligated to *StuI*-cleaved *pMTL23* (Chambers et al., 1988) and a recombinant plasmid selected (*pTRP23*) in which two tandem copies of *trpA* had been inserted. The resultant double terminator, together with part of the *pMTL23* polylinker region, was excised as a 107 bp *NruI*-*EcoRI* fragment and inserted between the *EcoRI* and *EcoRV* sites of plasmid *pMTL1003* (Brehm et al., 1991). As the c. 350 bp *EcoRI*-*EcoRV* fragment of *pMTL1003* is deleted during this manipulation, the resultant plasmid, *pMTL32*, does not carry a copy of the *trp* promoter.

The recombinant plasmid obtained, designated *pCBB1*, was shown by digestion with appropriate endonucleases to contain restriction enzyme recognition sites consistent with the map illustrated in Fig. 3. Its entire insert was excised by digestion with *BamHI* and *BglII* M13 recombinant templates containing random inserts derived using a sonication procedure (Minton et al., 1986). Using these templates, and custom synthesised oligonucleotides the entire nucleotide sequence of the insert was determined on both strands. Translation of the resultant sequence indicated the presence of an open reading frame (ORF) encoding a polypeptide of 549 amino acids in size. The aminoterminal of this polypeptide exhibited perfect conformity to that experimentally determined for purified BoNT/B L chain (Sathiyamoorthy and DasGupta, 1985). Amino acids 442 through 459 were identical to that

determined for purified BoNT/B H chain (Sathymoorthy and DasGupta, 1985). Thus the insert carried by pCBB1 was deemed to encode the entire L chain of BoNT/B and 108 amino acids from the H chain.

Cloning and sequencing of the botB H chain.

Having established that the 2.1 *Bgl*II-*Xba*I fragment encoded the entire BoNT/B L chain and the aminoterminal of the H chain, it was apparent that the adjacent 1.8 kb *Xba*I fragment (Fig. 3) should encode the majority of the remaining H chain. Type B chromosomal DNA was cleaved with *Hind*III, fragments of approximately 3.5 kb isolated, digested with *Xba*I and fragments of around 1.8 kb in size gel purified. The isolated DNA was ligated with *Xba*I-cleaved pMTL32, transformed into *E. coli* TG1 and recombinant plasmids identified by probing with the radiolabelled *botA* H chain probe. One such plasmid was designated pCBB2, and the nucleotide sequence of its insert determined, following its insertion in M13mp18, by employing custom synthesised oligonucleotide primers.

Translation of the nucleotide sequence obtained revealed the presence of an continuous ORF of 623 codons, in the same reading frame relative to the *Xba*I site of that of the insert of plasmid pCBB1. To confirm that the two sequences were indeed contiguous a 289 bp region of DNA encompassing the *Xba*I site was amplified from type B genomic DNA using the primers X1 (5'-CCAAGTGAAAATACAGAATCAC-3') and X2 (3'-CCCACCTTGCTATCATTTA-5') in a polymerase chain reaction (PCR), and cloned directly into ddT-tailed *Sma*I cut M13mp8. Nucleotide sequencing of a derivative template, using universal primer, demonstrated that the inserts of plasmids pCBB1 and pCBB2 were contiguous in the *C. botulinum* type B chromosome.

Completion of the botB sequence.

By combining the two sequences of pCBB1 and pCBB2, the derived contiguous ORF encoded 1170 amino acids, indicating that some 120 or so codons of the *botB* gene were missing. A DNA region encompassing the remaining 3'-end of the gene was cloned by inverse PCR. Type B chromosomal DNA was cleaved with *Hind*III, incubated with T4 ligase, and the resultant concatenated DNA used as a template in PCR with the oligonucleotides X3 (5'-ATAGAGATTTATATATTGGAG-3') and X4 (5'-TTATATACAGCCAAATGCTCCTTGC-3'). The 1.6 kb fragment generated was cloned directly into the specialised vector pCR1000 and the recombinant plasmid obtained designated pCBB3. A plasmid sequence reaction, undertaken with a primer previously employed in the determination of the nucleotide sequence

of the insert of plasmid pCBB2, confirmed the presence of the *botB* gene. Thereafter the nucleotide sequence of the region of pCBB3 encompassing the 3'-end of *botB* was determined by subcloning selected overlapping fragments into M13. To rule out the possibility that the insert of pCBB3 may have contained PCR-induced errors, a second version of this plasmid recombinant was derived by cloning the amplified DNA product from a further independent inverse PCR. Nucleotide sequencing of the appropriate regions of this second plasmid gave an identical sequence to that already derived from the primary isolate of pCBB3.

```

1  AGCAATTTATGGCATTAAAGGGATATAAACTTAAAAATAAGGAGGAATATTTATGCCAGTTACAATAAATAATTTAATTATAATGATCCTATTGTA
      RBS      H P V T I N N F N Y N D P I D N
101  M N I I M M E P P F A R G T G R Y Y K A F K I T D R I W I I P E R
      ATATAATATTATTATGATGGAGCCTCCATTTGCGAGAGGTACGGGGAGATATTATAAGCTTTTAAATCACAGATCGTATTGGATAATACCGGAAAG
      HindIII
201  Y T F G Y K P E D F N K S S G I F N R D V C E Y Y D P D Y L N T N
      ATATACTTTTGGATATAAACCTGAGGATTTTAAATAAAGTTCGGTATTTTAAATAGAGATGTTTGTGAATATTATGATCCAGATTACTTAAATACTAAT
301  D K K N I F L Q T M I K L F N R I K S K P L G E K L L E M I I N G I
      GATAAAAAAGATATATTTTTACAAACAATGATCAAGTTATTTAATAGAATCAAAATCAAAACCATTTGGGTGAAAAGTTATTAGAGATGATTATAAATGGTA
401  P Y L G D R R V P L E E F M T N I A S V T V N K L I S N P G E V E
      TACCTTATCTTGGAGATAGACGTGTTCCACTCGAAGAGTTTAAACACAACCATTTAGTGTAACTGTTAATAAATTAAATCAGTAATCCAGGAGAAAGTGGA
501  R K K G I F A N L I I F G P G P V L N E N E T I D I G I Q N H F A
      GCGAAAAAAGGTATTTTCGCAAAATTTAATAATTTTGGACCTGGGCCAGTTTTAAATGAAAATGAGACTATAGATATAGGTATACAAAATCATTITGCA
601  S R E G F G G I M Q M K F C P E Y V S V F N N V Q E N K G A S I F N
      TCAAGGGAAGGCTTCGGGGGTATAATGCAAAATGAAGTTTGGCCAGAATATSTAAGCGTATTTAATAATGTTCAAGAAAAACAAAGGCGCAAGTATATTTA
701  R R G Y F S D P A L I L M H E L I H V L H G L Y G I K V D D L P I
      ATAGACGTGGATATTTTTCAGATCCAGCCTTGATATTAATGCATGAACCTTATACATGTTTATCATGGATTATATGGCATTAAGTAGATGATTACCAAT
801  V P N E K K F F M Q S T D A I Q A E E I Y T F G G Q D P S I I T P
      TGTACCAATGAAAAAAATTTTTATGCAATCTACAGATGCTATACAGGCAGAAGACTATATACATTTGGAGGACAAGATCCAGCATCATACTCCT
901  S T D K S I Y D K V L Q N F R G I V D R L N K V L V C I S D P N I N
      TCTACGGTAAAGATATCTATGATAAAGTTTTCGAAAATTTAGAGGGATAGTTGATAGACTTAACAAGGTTTGTAGTTGCATATCAGATCCTAACATTA
1001  I N I Y K N K F K D K Y K F V E D S E G K Y S I D V E S F D K L Y
      ATATTAATATATATAAAAAATAATTTAAAGATAAATATAAATTCGTTGAAGATTCTGAGGGAAAAATAGTATAGATGTAGAAAGTTTGTATAAATTATA
1101  K S L M F G F T E T N I A E N Y K I K T R A S Y F S D S L P P V K
      TAAAAGCTTAATGTTTGGTTTACCAAACTAATATAGCAGAAAATTATAAAAAAACTAGAGCTTCTTATTTTAGTGAITCCTTACCACCAGTAAAA
      HindIII
1201  I K N L L D M E I Y T I E E G F N I S D K D M E K E Y R G Q N K A I
      ATAAAAAATTTATTAGATAATGAAATCTATACTATAGAGGAAGGGTTAATATATCTGATAAAGATATGAAAAAGAATATAGAGGTGAGATAAAGCTA
      H-CHAIN
1301  N K Q A Y E E I S K E H L A V Y K I Q M C K S V K A P G I C I D V
      TAAATAAACAGCTTATGAAGAAATTAGCAAGGACATTTGGCTGTATATAAGATACAAATGTGTAAGTGTAAAGCTCCAGGAATATGTATTGATGT
      HindIII
1401  D N E D L F F I A D K N S F S D D L S K M E R I E Y N T Q S N Y I
      TGATAATGAAGATTGTTCTTTATAGCTGATAAAAAATAGTTTTCAGATGATTTATCTAAAAACGAAAGATAGAATATAATACACAGAGTAATTATATA
1501  E N D F P I N E L I L D T D L I S K I E L P S E N T E S L T D F N V
      GAAATGACTTCCCTATAAATGAATTAATTTTAGATACTGATTAATAAGTAAATAGAATTACCAAGTGAAATACAGAATCACTTACTGATTTTAATG
1601  D V P V Y E K Q P A I K K I F T D E N T I F Q Y L Y S Q T F P L D
      TAGATGTTCCAGTATATGAAAAACACCGCTATAAAAAAATTTTACAGATGAAAAATACCATCTTCAATATTTTACTCTCAGACATTTCCCTCTAGA
      XbaI
1701  I R D I S L T S S F D D A L L F S N K V Y S F F S M D Y I K T A N
      TATAAGAGATATAAGTTTAAACATCTTCATTTGATGATGCATTATTATTTCTAACAAGTTTATTCATTTTTTCTATGGATTATATAAATCTGTAAT
1801  K V V E A G L F A G W V K Q I V N D F V I E A N K S N T M D K I A D
      AAAGTGGTAGAAGCAGGATTATTTGCAGGTTGGGTGAAACAGATAGTAAATGATTTTGTAAATCGAAGCTAATAAAGCAATACTATGGATAAAATTCAG
1901  I S L I V P Y I G L A L N V G M E T A K G M F E N A F E I A G A S
      ATATATCTCTAATGTTCTTATATAGGATTAGCTTTAAATGTAGGAAATGAAACAGCTAAAGGAAATTTGAAAATGCTTTTGAGATTGCAGGAGCCAG

```

Fig 5. Complete nucleotide sequence of the type B gene. The illustrated sequence was derived by amalgamation of the derived nucleotide sequences of the inserts of pCBB1 to pCBB3 (Fig. 3). The

with all other *bot* genes characterised to date, the high A+T content of the DNA (74.6%) results in an extreme bias towards the use of codons ending in A or T, and the frequent use of codons recognised as modulators in *E. coli*. The translational start codon is preceded by a sequence typical of clostridial ribosome binding sites (Young et al., 1989).

Alignment of the nucleotide sequences of the two *botA*-derived DNA probes used in Southern blot mapping with the equivalent regions of *botB*, confirmed that the greater degree of homology existed in the respective H chain encoding regions over those encoding L chain. Specifically, the 628 bp *HaeIII-HindIII botA* fragment demonstrated 65% homology with *botB*, whereas the 389 bp *HpaI-XhoII botA* fragment had 54.8% homology with *botB*. Comparative alignment demonstrated that, in general, the overall DNA homology between the H chain and L chain encoding regions of all sequenced neurotoxin genes reflected the level of amino acid sequence homology (Table 2), and averaged between 50 to 60% identity. One consequence of this relative dissimilarity between genes is that DNA probes specific to each toxin gene may be easily designed. However, although there is sufficient homology in certain regions to derive a generalised probe for the generic detection of neurotoxin genes, it has not proven possible to design a probe which hybridises to all *bot* genes and not to the TeTx gene (unpublished data).

The complete amino acid sequence of BoNT/B.

The deduced primary sequence of BoNT/B demonstrates that the toxin is composed of 1291 amino acid residues. By comparison to partial amino acid sequences derived from purified polypeptides from other *C. botulinum* type B strains, it is apparent that variations in toxin structure occur. Thus although amino acid residues 2 through 17 exhibit perfect conformity to the sequence derived by Edman degradation of purified BoNT/B L chain of strain B/Okra (Sathyamoorthy and DasGupta, 1985), the amino acid at position 23 of the H chain was determined (DasGupta and Datta, 1988) to be Arg rather than the Ser residue seen here (position 464, Fig. 4). Similarly, the BoNT/B of strain B/657 possesses a Met amino acid at position 30 of the L chain (DasGupta and Datta, 1987) compared to Thr in the case of BoNT/B of Danish and B/Okra. Variations in the primary amino acid sequence of other types of BoNT have been noted, eg., between BoNT/A of strain 62A (Binz et al., 1990) and strain NCTC 2916 (Thompson et al., 1990), and between BoNT/E of strains Beluga, Mashike, Iwanai, Otaru and NCTC 11219 (this study). In the case of BoNT/B, such variations go some way to explaining observed dissimilarity in the immunological properties of BoNT/B isolated from different strains (Hatheway et al., 1981; Notermans et al., 1984).

1.4 CLONING/ SEQUENCING OF THE BoNT/F GENE

1.4.1 Summary

A total of 4 overlapping regions from the *C. botulinum* type F genome have been amplified by PCR and cloned into plasmid vectors. Nucleotide sequence analysis of the inserts of the resultant plasmids (pCBF1-4) has allowed the derivation of a 3590 bp portion of the *botF* structural gene, encoding 1196 amino acid residues. From comparative alignment with BoNT/E, it is estimated that c. 20 codons are missing from the 5'-end of the gene, and 60 codons from the 3'-end of the gene. The unsequenced portion of the insert of plasmid pCBF3 is of sufficient size to comfortably encode the missing 3'-end of the gene. The 5'-end of the gene remains to be cloned. Furthermore, the sequence is only of a preliminary nature as approximately 50% has only been derived from analysis of DNA amplified from a single PCR, and may therefore contain Taq polymerase induced errors. The amino acid sequence available demonstrates that BoNT/F is highly homologous to BoNT/E. At present the incomplete H chain shares 68% identity with the equivalent region of the BoNT/E H chain, while the respective L chains exhibit 50% similarity. They therefore represent the most closely related neurotoxin pairing.

1.4.2 Results and Discussion

Cloning of H chain encoding DNA by PCR

The oligonucleotide primers HE2 and HE5 (Table 1) had previously been shown to effect the amplification of a 1.2 kb fragment in a PCR using both type B and E DNA as template. When these two primers were employed in PCR using type F chromosomal DNA, an identically sized fragment was generated. This fragment was blunt-ended by treatment with T4 DNA polymerase and, following its isolation from an agarose gel, inserted into the *Sma*I site of pMTL32. The entire insert, and specific subfragments, were excised from the recombinant plasmid (pCBF1, Fig 6) and subcloned into M13mp18 and M13mp19. Templates prepared from the various recombinant phages were then subjected to nucleotide sequence analysis using universal primer. In certain instances the sequence obtained with a particular template was extended using a synthesised sequence specific oligonucleotide. Translation of the nucleotide sequence obtained revealed the presence of a continuous ORF exhibiting substantial homology (74.4%) to BoNT/E.

Cloning of contiguous *BoNT/F* encoding DNA

To facilitate the cloning of regions of *botF* contiguous with that present in the insert of pCBF1, plasmid DNA was radiolabelled and used in Southern blot experiments to construct a restriction map of the type F genome (Fig. 6). The data obtained suggested that a 2.9 kb




Fig. 6. *BoNT/F* gene cloning strategy. The 4 PCR-amplified regions of strain Langeland chromosome, that were cloned in the recombinant plasmids pCBF1-4, are represented by appropriate boxes below the restriction map of the region of the genome encoding the *BoNT/F* gene (bold line = light chain, hatched box = heavy chain). An open box (pCBF1) indicates the amplified region was obtained in a standard PCR, the dotted boxes (pCBF2-4) represent regions amplified by inverse PCR. The vertical dotted lines identifies the boundaries of the concatenated restriction fragments employed as the substrate for inverse PCR, using primer pairs HF1 to HF6 (see text for sequences). Primers HE2 and HE5 are those used in the cloning of the equivalent region of *botE*. Abbreviated restriction sites are: RI, *EcoRI*; RV, *EcoRV*, and; HIII, *HindIII*.

EcoRI fragment encompassed the cloned insert of pCBF1. As this fragment encoded significant further portions of the *botF* gene, it was targeted for cloning by a strategy involving inverse PCR. Type F chromosomal DNA was cleaved with *EcoRI*, incubated with T4 DNA ligase and the resultant concatenated DNA used as the template in a PCR with two oligonucleotides primers (HF1, 5'-CTCCTAATAATTCAAATGCCTCCTT-3'; HF2, 5'-AACTAGTITTTAATTATACACAAAT-3') complementary to sequences at the proximal and

distal end of the pCBF1 insert (Fig. 6). The 1.9 kb fragment amplified was blunt-ended and cloned into the *Sma*I site of pMTL32 to yield the recombinant plasmid pCBF2. The insert of this plasmid was excised by digestion with *Bgl*III and M13 templates containing random inserts generated using the sonication procedure. The subsequent nucleotide sequence data obtained, in combination with that previously obtained from the pCBF1 insert, resulted in a contiguous sequence of 2,975 bp in length. Upon translation an uninterrupted ORF was evident encoding a polypeptide of 994 amino acid residues exhibiting 66.4% similarity to BoNT/E. From the alignment obtained between this polypeptide sequence and BoNT/E it was evident that a DNA region equivalent to some 150 codons was missing from the 3'-end of the *botF* gene, and approximately 122 codons from the 5'-end.

Cloning of the 5'- and 3'-end of botF

To identify restriction fragments encoding the 5'- and 3'-ends of *botF* Southern blot experiments were undertaken using type F genomic DNA cleaved with various restriction enzymes and two M13 recombinant clones, M13F16 and M13F44, as radiolabelled probes. These two M13 clones contained approximately 500 bp DNA inserts derived from either the proximal or distal ends of the sequenced 2.9 kb *Eco*RI fragment. Using probe M1316 a *Nsp*HI fragment of approximately 650 bp in size was identified with the potential to encode the 5'-end of *botF*, while the probe M13F44 identified a 2.0 kb *Hind*III fragment deemed to carry the 3'-end of the gene. To clone the appropriate coding region of each fragment, PCR was undertaken with concatenated *Nsp*HI- and *Hind*III-cleaved type F chromosomal DNA with the primers HF5 (5'-TCAGGTCCTGCTCCCAATACAAGAAG-3') + HF6 (5'-CCCCGTTAGAAAATAATGGATTCA-3') and HF3 (5'-TTACTACTATATATTCC-3') + HF4 (5'-GATCCAAGTATCTTAAAAGACTTTT-3'), respectively (Fig. 6). The fragments amplified (600 bp in the case of HF5 + HF6, and 1.5 kb in the case of HF3 + HF4) were cloned directly into pCR1000 to give the recombinant plasmids pCBF4 and pCBF3, respectively (Fig. 6).

The entire insert of pCBF3, and a 0.8 kb *Eco*RI-*Hind*III subfragment of the pCBF4 insert, were subcloned into M13mp18 and M13mp19 and the resultant templates sequenced using universal primer. In the case of the pCB4 -derived templates, the sequence obtained proved to be contiguous with that of the insert of pCBF2, however, alignment of the translated encoded polypeptide with BoNT/E revealed that the extreme 5'-end of the gene had not been cloned. Thus if BoNT/F has an identical number of amino acid residues at its aminoterminal, 20 codons are missing from the start of the gene. In the case of the pCBF4-derived templates, the M13mp19 recombinant template extended the *botF* gene by 399 nucleotides.

Current status of the *botF* nucleotide sequence

The extent of the *botF* nucleotide sequence currently known is illustrated in Fig. 7. A total of 3590 bp in length, it encodes 1196 amino acid residues. By comparison to BoNT/E, the

```

M Q I P Y E E K S K K Y Y K A F E I M R N V W I I P E R N T I G T
ATGCAGATACCATATGAAGAAAAAGTAAAAATATTATAAAGCTTTTGAGATTATGCGTAATGTTTGGATAATTCCTGAGAGAAATACAATAGGAACGG 100
NspH HindIII
D P S D F D P P A S L E N G S S A Y Y D P N Y L Y T T D A E K D R Y L
ATCCTAGTGATTTTGATCCACCGGCTTCATTAGAGAACGGAAGCAGTGCTTATTATGATCCTAATTATTTAACCAGTGTGCTGAAAAAGATAGATATTT 200

K T T I K L F K R I N S N P A G G E V L L Q E I S Y A K P Y L G N E
AAAAACAACGATAAAATTTTAAAGAGAATTAATAGTAATCCTGCAGGGGAAGTTTGTACAAGAAATATCATATGCTAAACCATATTTAGGAAATGAA 300

N T P I N E F H P V T R T T S V M I K S S T N V K S S I I L M L L
CACACGCCAATTAATCCATCCAGTTACTAGAACTACAAGTGTTAATATAAAATCATCACTAATGTTAAAAGTTCAATAATTTGAATCTTCTTG 400
EcoRI
V L G A G P D I F E N S S Y P V R K L M D S G G V Y D P S N D G F G
TATTGGGAGCAGGACCTGATATATTTGAAATTTCTTACCCCGTTAGAAAACTAATGGATTGAGTGGAGTTTATGACCAAGTAATGATGGTTTTGG 500

S I N I V T F S P E Y E Y T F M D I S G G Y N S S T E S F I A D P
ATCAATTAATATCGTGACATTTTACCTGAATATGAATATACCTTTAATGATATTAGTGGAGGGTATAACAGTAGTACAGAATCATTTATTGCGAGATCCT 600

A I S L A H E L I H A L H G L Y G A R G V T Y K E T I K V K Q A P
GCAATTTCACTAGTCATGAATTTGATACATGCCTGCTGATGATTATACGGGGCTAGGGGAGTTACTTATAAAGAGACTATAAAGTAAAGCAAGCACCTC 700
NspH
L M I A E K P I R L E E F L T F G G Q D L M I I T S A N K E K I Y N
TTATGATAGCCGAAAAACCCATAAGGCTAGAAGCTTTTAAACCTTTGGAGGTGAGGATTAAATATTATTACTAGTGCTATGAAGGAAAAATATATATA 800

M L L A N Y E K I A T R L S R V N S A P P E Y D I N E Y K D Y F Q
CAATCTTTTAGCTAATATGAAAAATAGCTAGACTAGTAGAGTTAATAGTGCTCCTCCTGAATATGATATTAAATGAATATAAGATTATTTTCAA 900

W K Y G L D K N A D G S Y T V N E K F M E I Y K K L Y S F T E I
TGGAGATATGGGTAGATAAAAAATGCTGATGGAAGTTATCTGTAATGAAAAATAAATTTAATGAATTTATAAAAATATATAGCTTTACAGAGATTG 1000

D L A N K F K V K C R N T Y F I K Y G F L K V P N L L D D D I Y T V
ACTTAGCAATAAATTTAAAGTAAATGATAGAAATCTTATTTTATTAATATGGATTTTAAAGTTCCTCAATTTGTTAGATGATGATTTTACTGCT 1100

S E G F N I G N L A V N H R G Q N I K L N P K I I D S I P D K G L
ATCAGAGGGGTTTAAATATAGGTAATTTAGCAGTAAACAATCGCGGACAAAAATATAAAGTTAAATCCTAAATTTATTGATTCATTCAGATAAAGGCTCTA 1200

V E K I V K F C K S V I P R K G T K A P P R L C I R V N H R E L F
GTGGAAAGATCGTTAAATTTTGTAGAGCGTTATTCTAGAAAAGGTACAAAGGCCACCGCGACTATGCATTAGAGTAAATAATAGGAGATTATTTT 1300

F V A S E S S Y N E N D I N T P K E I D D T T N L N N Y R N N L D
TTGTAGCTTCAGAAAGTAGCTAATGAAATGATATTAATACACCTAAAGAAATGACGATACAACAAATCTAAATAAATTATAGAAATAATTTAGA 1400

E V I L D Y N S E T I P Q I S N Q T L N T L V Q D D S Y V P R Y D
TGAAGTTATTTTAGATTATAATAGTGAGALATACCTCAAAATATCAAAATCAAACTTAAATACACTTGTACAAGACGATAGTTATGTGCCAAGATATGAT 1500

S N G T S E I E E H N V V D L N V F F Y L H A Q K V P E G E T N I
TCTAATGGAACAGTGAAATAGAGGAACATAATGTTGTTGACCTTAATGTAATTTTCTATTTACATGCACAAAAAGTACCAGAAGGTGAAACTAATATA 1600

S L T S S I D T A L S E E S Q V Y T F F S S E F I N T I N K P V H A
GTTTAAGCTTCTTCAATTGATACGGCATTATCAGAAGAATCGCAAGTATATACATTCTTTTCTCAGAGTTTATTAATCTATCAATAAACCTGTACACGC 1700

A L F I S W I N Q V I R D F T T E A T Q K S T F D K I A D I S L V
AGCACTATTTATAAGTTGGATAAATCAAGTAATAAGAGATTTTACTACTGAAGCTACACAAAAAGTACTTTTGATAAGATTGCAGACATATCTTTAGTT 1800
ScaI
V P Y V G L A L N I G N E V Q K E N F K E A F E L L G A G I L L E
GTACCATATGTAGGTCTTGCTTTAAATATAGGTAATGAGGTACAAAAAGAAATTTTAAAGGAGGCAATTTGAATATTAGGAGCGGGTATTTTATTAGAAT 1900

F V P E L L I P I L V F T I K S F I G S S E N K N K I I K A I N N
TTGTGCCAGAUCTTTTAATTCCTACAATTTTAGTGTTTACAATAAAATCCTTTATAGGTTTCATCTGAGAATAAAAAATAAATCATTAAAGCAATAATAA 2000

S L M E R E T K W X E I Y S W I V S N W L T R I N T Q F N K R K E
TTCATTAATGGAAGAGAAACAAAGTGGAAGAAATATATAGTTGGATAGTATCAAATTTGGCTTACTAGAATTAATACACAATTTAATAAAGAAAAAGAA 2100

```

Fig. 7. Partial nucleotide sequence of the *type F* gene. The illustrated sequence was derived by amalgamating the nucleotide sequences of the inserts of plasmids pCBF1 to pCBF4 (Fig. 6). The BoNT/F amino acid sequence is given in the single code above the central nucleotide of the

Q M Y Q A L U N Q V D A I K T V I E Y K Y N N Y T S D E R N R L E
 CAAATGTATCAAGCTTTGCAAAATCAAGTAGATGCAATAAAACAGTAATAGATATAAATAAATACTTCAGATGAGAGAAATAGACTTGAAT 2200
 HindIII
 S E Y N I N I N I R E E L N K K V S L A M E N I E R F I T E S S I F Y
 CTGAATATAATATCAATAATAAGAGAAGATTGAACAAAAAGTTCTTTAGCAATGGAAAAATAGAGAGATTATAACAGAGAGTTCTATATTTTA 2300
 L M K L I N E A K V S K L R E Y D E G V K E Y L L D Y I S E H R S
 TTTAATGAAGTTAATAATGAAGCAAGTTAGTAAATTAAGAGAATATGATGAAGCGTTAAGGAATATTTGCTAGACTATATTCAGAAATAGATCA 2400
 I L G M S V Q E L N D L V T S T L N N S I P F E L S S Y T N D K I
 ATTTTAGGAAATAGTGACAAGAATTAATGATTTAGTGACTAGTCTGGAATAATAGTATCCATTTGAACCTTTCTTCATATACTAATGATAAAATTC 2500
 ScaI
 L I L Y F N K L Y K K I K D N S I L D M R Y E N N K F I D I S G Y G
 TAATTTTATATTTAATAATATATATAAAAAAATAAGATAACTCTATTTAGATATGCGATTGAAAAATAAAATTTATAGATATCTCTGGATATGG 2600
 EcoRV
 S N I S I N G D V Y I Y S T N R N Q F G I Y S S K P S E V N I A Q
 TTCAAAATATAGCATTATAGGAGATGTATATTTATTCAACAAATAGAAATCAATTTGGAATATATAGTAGTAAGCCTAGTGAAGTTAATAGCTCAA 2700
 N N D I I Y N G R Y Q N F S I S F V V R I P K Y F N K V N L N N E
 AATATGATATTATACAAATGGTAGATATCAAAATTTTAGTATTAGTTCTGGGTAAGGATTCCTAAATCTTCAATAAAGTGAATCTTAATAATGAAT 2800
 EcoRV
 Y T I I D C I R N M N S G W K I S L N Y N K I I W T L G D T A G N N
 ATACTATAATAGATTGTATAAGGAATAATAATTCAGGATGGAAATATCACTTAATTATAAAAAATAATTTGGACTTTACAAGATACTGCTGGAAATTA 2900
 Q K L V F N Y T Q M I S I S D Y I N K W I F V T I T N N R L G M S
 TCAAAACATAGTTTTTAATTATACACAATGATTAGTATATCTGATTATATAAATAAATGGATTTTGTAACTATTACTAATAATAGATTAGGCAATTC 3000
 R I Y I N G N L I D E K S I S N L G D I N V S D N I L F K I V G C
 AGAATTTACAATCAATGGAAATTTAATAGATGAAAAATCAATTTCCAATTTAGGTGATATTCATGTTAGTGATATATATTATITAAATTTGTTGGTTGTA 3100
 M D T R Y V G I R Y F K V F D T E L G K T E : E T L Y S D E P D P S
 ATGATACAAGATATGTTGGTATAAGATATTTTAAAGTTTGTATACGGAATTAGGTAAAACAGAAATGAGACTTTATATAGTGATGAGCCAGATCCAAG 3200
 I L K D F W G M Y L L Y M K R Y Y L L N L L R T D K S I T O M S N
 TATCTTAAAGACTTTTGGGGAAATTTTGTATATATAAAAAAGATATTATTTTGAATTTACTAAGAACAGATAAGTCTATTACTCAGAATTCAAAC 3300
 EcoRI
 F L N I N Q Q R G V Y Q K P N I F S M T R L Y T G V E V I I R K N
 TTTCTAAATATTAATCAACAAAGAGGTGTTTATCAGAAACCAATATTTTTTCCAACACTAGATTATATACAGGAGTAGAAGTTATTATAAGAAAAATG 3400
 G S T D I S M T D N F V R K N D L A Y I N V V D R D V T Y R L Y A D
 GATCTACAGATATATCTAATACAGATAAATTTGTTAGAAAAATGATCTGGCATATATTAATGTAGTAGATCGTGATGTAATATCGGCTATATGCTGA 3500
 I S I A K P E K I I K L I R T S M S N N S L G Q I I V M D S
 TATATCAATTTGCAAAACAGAGAAAAATAAATAAATTAATAAGAACATCTAATTCAAACAATAGCTTAGGTCAAATATAGTTATGGATTC 3590

Fig 7. Partial nucleotide sequence of the type F gene. (continued)

corresponding codon. It should be noted that the sequence is of a preliminary nature, having been derived in certain regions from a single PCR-amplified DNA fragment.

sequence currently lacks the coding potential for c. 20 amino acids at the aminoterminal, and c. 60 amino acids at the carboxyterminus. In addition, approximately half the sequence has only been derived from a single PCR-derived cloned fragment. Two further isolates of plasmid clones pCBF1 to pCBF4 have now been derived from two further independently PCR amplified fragments, and the inserts of a single representative of each is being sequenced. To date only 3 discrepancies with the sequences obtained from the original clones have been detected. Thus the error rate seems considerably lower than that observed during the amplification of type E DNA. The reason for this is unclear, the condition of PCR being identical, but may be caused by the use of different sources of Taq polymerase. Thus, during the period that type E DNA was being amplified enzyme from Palliard Chemical Co was in widespread use within this laboratory. More recently, the supplier of Taq polymerase has consistently been Cetus.

The unsequenced portion of the insert of plasmid pCBF3 is of sufficient size to easily accommodate the missing 3'-end of the gene. Further sequencing of this clone should therefore allow the derivation of the carboxyterminus of BoNT/F. The DNA region encoding the amino terminus still remains to be cloned. In view of the high degree of DNA homology between *botE* and *botF*, it is planned to amplify an appropriate fragment in a standard PCR reaction using a "sense" primer based on the 5' non-coding region of *botE*, and an anti-sense primer based on the sequence derived from pCBF4.

1.5 CLONING/ SEQUENCING OF THE BoNT/G GENE

1.5.1 Summary

A 1050 bp fragment was PCR amplified from type G chromosome, using primers designed for the detection of the type A gene, cloned into pCR1000 and 250 bp of sequence information determined from either end. This sequence proved to be indistinguishable from *botA*, indicating that the chromosome had been prepared from a type G culture contaminated with type A cells.

Attempted cloning of a H chain encoding region of the BoNT/G gene

During the course of a parallel programme of work, in which oligonucleotide primers for the detection of toxin genes were being evaluated, it was noted that primers based on *botA* and *botB* sequence consistently amplified specific DNA fragments from type G chromosomal DNA. In one particular case the intensity and size of the fragment generated was equivalent to that seen with the intended target DNA, that of type A chromosome. This 1050 bp fragment was therefore cloned directly into pCR1000 and the proximal and distal regions of the insert of the resultant recombinant plasmid analysed in a plasmid sequence reaction using universal and reverse primer, respectively. A total of some 250 bp of sequence information was obtained with each primers, however, the two sequences proved to be identical to *botA*. It was concluded that the culture from which the chromosomal DNA had been prepared was contaminated with *C. botulinum* type A.

1.6 AMINO ACID HOMOLOGIES BETWEEN CHARACTERISED NEUROTOXINS

Pairwise comparisons of the respective L and H chain components of all 7 toxins was undertaken and the results summarised in Table 2 (it should be noted that the amino acid

sequences of the L and H chain of BoNT/F are incomplete). From this it can be seen that, with notable exceptions, the overall level of identity between L chains varies from around 30 to 35%. The four exceptions are the degree of homology seen between BoNT/E and BoNT/F (56%), BoNT/E and TeTx (40%), BoNT/C and BoNT/D (47%) and BoNT/B and TeTx (50%). The fact that certain BoNT's (BoNT/B, BoNT/E and BoNT/F) exhibit a greater degree of homology to the TeTx L chain than to other BoNT L chains is particularly striking. These homologies serve to emphasise the close relationship that exists between the pharmacological action of BoNT and TeTx. With the exception of TeTx, the H chains exhibit a much broader spread of % similarity values than the L chains. The highest degree of

NEUROTOXIN HOMOLOGIES

HEAVY LIGHT	A	B	C	D	E	F	TET
A		48	34	35	46	44	35
B	31		39	40	44	40	36
C	32	32		56	36	34	32
D	35	35	47		37	35	36
E	33	33	32	33		68	35
F	32	37	33	34	56		35
TET	30	50	34	34.5	40	42.5	

Table 2. Amino acid homology between the L and H chain components of the different types of BoNT and TeTx. Figures represent the % identity between di-chain components. The upper quadrant contains H chain comparisons, the lower L chain homologies. A, B, C, D, E, and F refer to the respective BoNT, TET represents TeTx. The data from BoNT/F is incomplete.

similarity is that found between BoNT/E and BoNT/F (68%), closely followed by the 56% similarity between the H chains of BoNT/C and BoNT/D. The overall dissimilarity of the TeTx H chain to BoNT's is consistent with the view that this region is responsible for the essential difference between these neurotoxins, viz, their site of action.

Purely on the basis of H chain comparisons, the BoNT's may be conveniently split into 3

pairings, viz, BoNT/A and BoNT/B, BoNT/C and BoNT/D, and BoNT/E and BoNT/F. The latter two pairings also appear to hold for the L chains, however, the BoNT/A and BoNT/B L chains represent the most dissimilar pairing. These relationships are best illustrated by the phylogenetic tree illustrated in Fig. 8. The variance seen in the relative order of relatedness between toxins dependent of which component of the dichain that is compared is intriguing. It suggest that either L and H chain domains of an individual neurotoxin have evolved at disproportionate rates, or that at various stages during evolution hybrid toxins have arisen by fusion of distinct H and L chain encoding regions.




Fig. 8. Phylogenetic relationships between the H and L chains of clostridial neurotoxins. The distance of the line along the x axis is indicative of degree of divergence.

An alignment of the entire amino acid sequences of BoNT/A, B, C, D, E and TeTx, and the partial amino acid sequence of BoNT/F is presented in Fig. 9. Regions of sequence similarity have been boxed. This demonstrates that the neurotoxins are composed of highly conserved amino acid domains interspersed with amino acid tracts exhibiting little overall similarity. Disregarding the incomplete BoNT/F sequence, within the L chain region (average size 442), 68 amino acids are totally conserved. 11 of these conserved amino acids reside in a region (position 216 to 234 of BoNT/B) which encompasses a histidine rich motif. The three conserved His residues of this region have previously, on the basis of their conservation in BoNT/A, BoNT/E and TeTx, been suggested to play some role in the presumed catalytic activity of the L chain (Binz et al., 1990). Their conservation in all 7 neurotoxins does not detract from this hypothesis. Preliminary work, however, in which site-directed mutagenesis has been used to effect amino acid substitutions at all three His positions did not effect the toxicity of a BoNT/A subunit in an *Aplysia californica* buccal ganglion model system (Binz et




Fig. 9. Full alignment of all known clostridial neurotoxin sequences.




Fig. 9. Full alignment of all known clostridial neurotoxin sequences.. The illustrated alignment was essentially derived using the computer programme CLUSTAL (Higgins and Sharp, 1988), and has been gapped to maximise homology. Dashes correspond to regions of the BoNT/F sequence which have yet to be determined. Highly conserved regions have been boxed, and include areas in which conservative replacements have occurred, in addition to sequence identity. Amino acids conserved in at least 6 out of 7 toxins have been emboldened. Numbering above the alignment corresponds to BoNT/A. The Cys amino acids presumed to be involved in the formation of the disulphide bridge between neurotoxin L and H chains are marked by upward facing arrows.

al., 1991).

Ignoring the incomplete BoNT/F sequence, within the H chain region (average size 845 amino acids) 110 amino acids are absolutely conserved. Most notable is the high degree of conservation of Trp amino acids. Thus, for instance, of the 12 Trp residues which occur in the BoNT/E H chain, 9 are absolutely conserved in all toxins, while the remaining 3 are conserved in all but one of the neurotoxins at each position. The only Trp that occurs in the BoNT/E L chain is conserved in all neurotoxins. The functional significance of the apparent evolutionary pressure for maintaining this amino acid, or chemically similar residues, at these positions in BoNT and TeTx remains unknown. However, previous studies in which BoNT Trp residues have been selectively modified by chemical means has established a crucial role in both toxicity and immunogenicity (see Dasgupta, 1990). Indeed, in one study the inactivation of a single Trp resulted in near complete detoxification (Shibaeva et al., 1981, cited in DasGupta, 1990). The selective disruption of conserved Trp amino acids in BoNT by site-directed mutagenesis should help identify which residue(s) are important in toxicity and antigenicity.

The most notable tract of sequence divergence between the toxins resides, with the exception of the extreme 10 or so amino acids, in the COOH-termini of the toxins (position




Fig. 10. *Hydrophobicity plots of all currently characterised clostridial neurotoxins.*

Hydrophobicity was calculated using the computer program of Kyte and Doolittle (22) with a window size of 9 amino acids. The average value for each toxin was:- BoNT/A, -0.37; BoNT/B, -0.42; BoNT/C, -0.41; BoNT/D, -0.36; BoNT/E, -0.45, and; TeTx., -0.37. The conserved hydrophobic region is indicated below each profile by a barred line. The respective residues involved are 652 through 687 (BoNT/A), 642 through 671 (BoNT/B), 648 through 678 (BoNT/C), 646 through 674 (BoNT/D), 624 through 654 (BoNT/E) and 660 through 691 (TeTx).

1117 onwards of BoNT/A). Divergence in this latter area would appear consistent with the notion that this domain is involved in BoNT binding, and that the different toxins target different acceptors on the cell surface. The presence of the conserved motif WXFI/VXXXXGW at the extreme COOH-terminus of all neurotoxins (except BoNT/C, where the terminal GW is missing, and BoNT/F which has yet to be sequenced in this region) is especially noteworthy, considering the degree of diversity of the preceding 100 amino acids.

The algorithms of Chou and Fassman (1978) and Garnier et al. (1978) were employed to derive predictive representations of BoNT and TeTx secondary structure (data not shown).

The results obtained went some way towards confirming the observations of a comparative structural analysis undertaken with purified BoNT/A and BoNT/E (Singh et al., 1990). Thus, the BoNT/E is predicted to contain a lower α -helix content than BoNT/A (BoNT/E, 20%; BoNT/A 27%), and a correspondingly higher content of β -sheet (BoNT/E, 52%; BoNT/A, 46%). No common pattern between the predicted structures of each neurotoxin was, however, apparent. In contrast, a hydrophilicity analysis by the method of Kyte and Doolittle (1982) demonstrated a high degree of conservation between all 7 neurotoxins in their arrangement of polar and nonpolar amino acids (see Fig. 10). A similar previous analysis of TeTx (Eisel et al., 1986) and BoNT/A (Thompson et al., 1990) had concluded that the H chain of these particular toxins contained a common domain (TeTx, 660 through 691; BoNT/A 652 through 687; Fig. 9) of sufficient length and hydrophobicity to possess membrane spanning potential. The equivalent hydrophobic domains (Fig. 9) are also conserved in BoNT/B (642 through 671) BoNT/E (624 through 654), BoNT/F (643 through 673), BoNT/C (648 through 678) and BoNT/D (646 through 674).

2. EXPRESSION SYSTEM DEVELOPMENT

2.1 MATERIALS AND METHODS

Bacterial strains, plasmids and culture conditions.

The *E. coli* and *Bacillus subtilis* strains routinely used as the host for recombinant experiments were TG1 ($\Delta[lac-pro]$ *supE thi hsdD5*/ $F'-traD36 proA^+ B^+ lacP lacZ\Delta M15$) and 168 *trpC*, respectively. The *Clostridium acetobutylicum* strain employed was NCIB 8052. The strains of *Clostridium sporogenes* tested were; BM1091, BM1706, BM1758, BM1759, BM1761, BM1763, BM1764, BM1765, BM1767, BM1768, BM1769, BM1774, BM1775, BM1776, BM1780, BM1781, BM1783, BM1784, BM2130 and BM2131. All strains were obtained from Dr. M Hudson, Pathology Division, PHLS CAMR. Recombinant plasmids employed were the pMTL20 series of cloning vectors (Chambers et al., 1988), the replicon cloning vectors pMTL20/21E and pMTL20/21C (Swinfield et al., 1990), pAMB1-derived shuttle vectors pMTL500E/C and pCTC1 (Oultram et al., 1988a; Swinfield et al., 1990; Williams et al., 1989a & b), and the *Clostridium* shuttle vectors pCB3 and pCTC501 (Young et al., 1989).

All clostridial cultures were routinely grown in 2x YTG medium (1.6% tryptone, 1.0% yeast extract, 0.5% NaCl, and 0.5% glucose). In certain instances commercially obtained (Oxoid) reinforced clostridial medium (RCM) was employed, and on other occasions the basal medium of O'Brien and Morris (1971). All manipulations were undertaken under anaerobic conditions using an Anaerobic Work Station Mark III (Don Whitley Scientific, UK). The incubation temperature was routinely 37°C.

Plasmid isolation methodology.

Plasmid DNA was isolated from *E. coli* as described in 1.2 of this report. Plasmid DNA from clostridial strains was isolated by an alkaline lysis procedure. Cells from a 10ml volume of culture, grown overnight in 2x YTG, were harvested by centrifugation and resuspended in 100 μ l of 50mM Tris-HCl, 25% (w/v) sucrose, 5 mM EDTA, pH 7.0, and lysozyme added to 10mg/ml. Following an incubation period of 60 min, at 37°C, a 200 μ l aliquot of freshly prepared 0.2 N NaOH, 1% SDS, was added and the tube inverted before being placed on ice for 5 min. A 150 μ l aliquot of ice-cold potassium acetate solution (5M potassium acetate: glacial acetic acid: dH₂O, 60:11.5:28.5), was added, mixed by vortexing and the tube stored on ice for 5 min. Following centrifugation, for 10 min in a microfuge, the

supernatant to was transferred to a fresh 1.5 ml eppendorf tube and an equal volume of phenol/chloroform (1:1) added. After vortexing and centrifugation in a microfuge the upper aqueous layer was carefully removed, mixed with 2 volumes of ethanol and allowed to stand at room temperature for two min. The DNA was precipitated by centrifugation, dried and resuspended in an appropriate volume of TE buffer.

Electroporation

A loopful of fresh culture was used to inoculate 500 μ l of 2 X YTG and this was then used to set up dilutions from 10^{-1} to 10^{-6} in 5 ml volumes by serial dilution. Cultures were grown overnight. The two lowest dilutions which had grown were used as inoculum for 100ml 2x YTG which was grown to an OD at 600nm of 0.5 - 0.6 (mid-exponential growth), cooled on ice for a few minutes, then harvested by centrifugation at 5000rpm for 10 min. The cell pellet was washed in 5ml ice-cold electroporation buffer (270 mM sucrose, 1 mM $MgCl_2$, 7 mM sodium phosphate buffer, pH 7.4) and harvested by centrifugation as above. The pellet was finally resuspended in 5ml ice-cold electroporation buffer and held on ice. One μ g DNA was added to each cuvette (0.2 cm inter-electrode diameter) followed by 300 μ l cell culture. The cuvettes were sealed with plastic insert. A single pulse was delivered: 1.25kV, 100ohms, 25 μ FD. (Time constant approx. 1.7ms). The culture was removed from cuvette by washing with 1ml 2x YTG and added to a final volume of 3ml of 2x YTG (ie a 1 in 10 dilution). A three hour expression period was followed by harvesting by centrifugation as above. The pellet was resuspended in 200 μ l of 2x YTG and 100 μ l volumes plated on selective agar, containing freshly prepared catalase (final concentration of 400 units/ml).

As far as possible, all manipulations were carried out in an anaerobic cabinet and all media and buffers were allowed to equilibrate in anaerobic conditions overnight. The Biorad "Gene Pulser" was used routinely as the electroporation apparatus.

Conjugation

E. coli cultures were grown overnight to OD at 600nm of >4.0 and *C. acetobutylicum* cultures (mid-exponential phase) to an OD at 600nm of 0.6. The donor and recipient cultures were mixed in a 1000:1 ratio within a total volume of 2ml, passed through a sterile 0.45 μ m pore size filter (2.5cm in diameter) and the filter was incubated upright overnight on reinforced clostridial medium supplemented with 2 mg of catalase. Growth on the filter was harvested by vortexing in 500 μ l 25 mM potassium phosphate pH 7.0, 1 mM $MgSO_4$ and 100 μ l volumes were plated on clostridial basal medium supplemented with 10 μ g trimethoprim (to select

against *E. coli*) and selective antibiotic. As far as possible all manipulation should be carried out under anaerobic conditions.

2.2 GENE TRANSFER IN *CLOSTRIDIUM SPOROGENES*

2.2.1 Summary

A total of 20 different strains of *C. sporogenes* have been tested as potential recipients for DNA transfer. Having established that the BioRad Gene Pulser gives the highest rate of electrotransformation in *C. acetobutylicum* (compared to equivalent equipment supplied by Jouan, BTX and Flowgen), attempts were made to transform all strains with a variety of plasmids and differing electrical parameters. Pulses were undertaken at a constant voltage (1.25 kV) and capacitance (25 μ FD) but at variable resistance (100, 200 & 400 ohms). Under these conditions the % survival varied from 46 to 13%. Plasmid replicons employed were either from the Gram-positive, broad-host-range plasmid pAM β 1, or the *C. butyricum* plasmid pCB101. Selective markers were the *erm* (Em^R) gene of pAM β 1 or a *C. perfringens* *tetP* gene. No transformants were obtained. Attempts to conjugatively mobilise derivatives of these vectors, endowed with the RK2 origin of transfer (*oriT*), from *E. coli* to each strain were similarly unsuccessful.

2.2.2 Results and Discussion

Antibiotic resistance profiles of strains

The successful introduction of an extrachromosomal DNA into bacteria requires that the transformed cell acquires a detectable phenotypic trait. The selectable genetic markers most commonly used are genes specifying resistance to antibiotics. Before attempting to obtain transfer of plasmids into any particular strain of *C. sporogenes*, it was therefore important to establish the antibiotic resistance profiles of the strains to be employed. A 3 ml volume of molten H-top agar was inoculated with 0.1 ml of exponential phase cells (growing in 2 X YTG media) and overlaid onto a 2 X YTG agar plate. When the inoculated agar had solidified, antibiotic-impregnated filter discs (Mast Laboratories Ltd) were placed on the agar surface and the plates incubated overnight at 37°C. The qualitative estimates of zones of inhibition around the different type of disc are indicated in Table 3. These show that, with the notable exception of streptomycin (Sm) and novobiocin (Nc), the 20 strains tested exhibited varying degrees of sensitivity to all the antibiotics tested. Of particular importance was the demonstrable susceptibility of every strain to erythromycin (Em), chloramphenicol (Cm) and tetracycline

(Tc). Genes specifying resistance to these three antibiotics form the basis of all currently available clostridial vectors (Young et al., 1989; Rood and Cole, 1991).

Plasmid screening

In parallel to the above tests each strain was screened for the presence of indigenous extrachromosomal elements using a plasmid isolation procedure routinely used in this laboratory for analysing transformants of *C. acetobutylicum* (MATERIALS AND METHODS). The cell lysates obtained were electrophoresed on 1.4% (w/v) agarose gels in

STRAIN	Cm ₂₅	Em ₅	Fu ₁₀	Me ₁₀	Nc ₅	Pc ₁	Sm ₁₀	Tc ₂₅	Cf ₃₀	Mn ₅	Cl ₂
BM1763	++	++	+++	++	+	++	-	++	+++	++	++
BM1758	+++	+++	++	++	+	++	-	+++	+++	++	++
BM1767	++	++	+++	++	-	++	-	++	+++	++	++
BM1774	++	++	+++	++	+	++	-	+++	+++	++	++
BM1796	++	++	+++	++	+	++	-	+++	+++	++	÷+
BM1781	++	++	+++	++	+	++	+	+++	+++	++	++
BM1775	+++	++	+++	++	+	++	-	+++	+++	++	+
BM2131	+++	++	+++	++	+	++	-	+++	+++	++	+
BM1780	++	++	+++	++	+	+++	+	+++	+++	++	++
BM1759	+	+++	+++	+++	-	-	-	++	+++	+++	++
BM1706	-	+++	+++	+++	-	++	-	++	+++	++	++
BM1764	++	++	+++	++	+	+++	-	+++	+++	++	++
BM1776	++	+++	+++	++	-	++	-	+++	+++	++	+
BM1783	+++	++	+++	++	-	++	-	++	++	+++	++
BM1768	+++	++	+++	++	++	++	-	+++	+++	++	-
BM1761	++	++	+++	++	-	++	-	+++	+++	++	+
EM1091	++	++	+++	++	-	++	-	+++	+++	++	+
BM2130	+++	++	+++	++	-	+++	-	+++	+++	++	+

Table 3. Susceptibility of *C. sporogenes* strains to various antibiotics

- = no zone of inhibition; + = zone up to 10 mm in diameter; ++ = zone of 11-20 mm; +++ zone >20 mm (all zones include the disc diameter of 6.5 mm). Antibiotic abbreviations are Cm, chloramphenicol; Em, erythromycin; Fu, fusidic acid; Me, methicillin; Nc, novobiocin; Pc, penicillin; Sm, streptomycin; Tc, tetracycline; Cf, cefoxitin; Mn, metronidazole, and; Cl, clindamycin. Antibiotic concentrations are given in subscripts, following each abbreviation, in µg per ml.

addition to the standard 0.8% (w/v) gels normally employed in plasmid analysis. This higher concentration of agarose ensures that any circular DNA species, "masked" by chromosomal DNA on a 0.8% gel, migrates substantially slower than chromosome and is therefore easily visualised (Minton *et al.*, 1983a). No evidence for the presence of plasmid DNA was found in the lysates of any of the 20 strains. In a further series of experiments the methods of Roberts *et al.* (1986) and Weickert *et al.* (1986), were employed. These procedures have previously been used to detect plasmid DNA in *Clostridium perfringens* and *Clostridium absonum*, and in *Clostridium botulinum* Type A strains, respectively. Although both methods proved applicable to a control *C. acetobutylicum* NCIB 8052 culture containing pCB3, no plasmids were detected in the lysates of any of the *C. sporogenes* strains under investigation.

Evaluation of various electroporators

Since the development of our original procedure for effecting the introduction of plasmid DNA into *C. acetobutylicum* using a BioRad Gene Pulser (Oultram *et al.*, 1988a), a number of other manufacturers have brought alternative machines onto the market. It was therefore considered timely to undertake a comparative evaluation of more recent apparatus, on the assumption that an increase in transformation frequencies may accrue. Three such machines were tested, alongside the BioRad Gene Pulser, for their efficiency in transforming *C. acetobutylicum* NCIB 8052 with plasmid pMTL500E (see Fig. 15). The BTX electroporator may be essentially viewed as equivalent in specification to the BioRad apparatus. The Jouan electropulser differs from other commercially available apparatus in that it generates a square wave pulse, which theoretically provides a constant field during discharge. The Flowgen Cellject resembles the BioRad and BTX machine, in that it discharges an exponential wave, but differs in the facility for discharging a preprogrammed second pulse, immediately after the first.

Electroporator	Transformation Frequency (per μg DNA)
BioRad Gene Pulser	1.2×10^2
BTX Electroporator	0.8×10^2
Flowgen Cellject	0.5×10^2
Jouan Electropulser	0

Table 4. *C. acetobutylicum* transformation frequencies employing different electroporation apparatus.

Each machine was tested over a range of pulse parameters. With those machines that did mediate transformation, however, these parameters were essentially equivalent to those (1.25 kV, 100 ohms, 25 μ FD) which gave the highest levels of DNA transfer with the routinely used BioRad Gene Pulser, viz., identical for the BTX, and 1.25 kV, 90 ohms and 40 μ FD for the Cellject. In the case of the Jouan Electropulser no transformants were obtained under any of the conditions employed. Indeed, the machine appeared incapable of effecting DNA transfer even into *E. coli*. This failure would appear to have been largely due to the ineffective electroporation chamber supplied with the apparatus, which was cumbersome to use and suffered from sample leakage. The other two machines both proved effective in eliciting transformation of *C. acetobutylicum* NCIB 8052 (Table 4). However, under optimum conditions, use of the BioRad machine consistently resulted in the highest transformation frequencies. The subjection of cell suspensions to a second pulse, of various magnitudes, using the Cellject gave a slight increase (c. 10%-20%) in the number of transformants, but the frequency obtained was significantly lower than those achieved with the BioRad apparatus. It was concluded that the electroporators of other manufacturers offered no advantage over the BioRad Gene Pulser, and this apparatus was used in all subsequent experiments with *C. sporogenes*.

Attempted electrotransformation of strains of C. sporogenes.

Prior to attempting the transformation of any particular strain of *C. sporogenes*, it was of interest to estimate the effect of electrical pulses on cell viability. Cell suspensions, prepared as for *C. acetobutylicum*, were therefore divided in two, and one fraction subjected to pulses of various magnitudes before serial dilutions of both cell fractions were plated onto 2 X TYG agar. From the viable colony count obtained with the two cell fractions it was possible to estimate the % cell survival after each pulse. Some representative data is shown in Table 5.

STRAIN	% SURVIVAL		
	100 ohms	200 ohms	400 ohms
BM1781	46	19	16
BM2131	40	22	14
BM1706	45	20	21
BM1759	38	18	15
BM1091	37	19	13
NCIB 8052	8.5	3.5	1.95

Table 5. Percentage survival of *C. sporogenes* cells, compared to *C. acetobutylicum* NCIB 8052

The results obtained indicated that all the *C. sporogenes* strains under investigation exhibited a similar levels of fragility with respect to the pulse applied. It was further apparent *C. sporogenes* is generally a more robust organism than *C. acetobutylicum*.

These experiments established that the field strength applied was having some effect on cell viability. However, as there are no hard and fast rules as to the level of cell survival most appropriate for successful transformation, attempts to transform the 20 strains of




Fig. 11. The *Clostridium/E. coli* shuttle vector pMTL500ET. Constructed by isolating a 2.9 kb *SstI-PstI* fragment encoding *tetP* from the *C. perfringens* plasmid pJIR71 (Rood and Cole, 1991) and inserting it between the equivalent sites of pMTL500E (Oultram et al., 1988a).

C. sporogenes were undertaken using a pulse of constant voltage (1.25 kV) and capacitance (25 μ FD), but at the three different resistances employed in the cell viability experiments, viz., 100, 200 and 400 ohms. The plasmids employed were, pCB3 (Young et al., 1989), pMTL520 (Minton et al., 1990a) and pMTL500ET (Fig. 11). Plasmid pMTL500ET is based on the replicon of the *Enterococcal faecalis* plasmid pAMB1, widely recognised as possessing an extremely broad host range amongst Gram-positive bacteria. Plasmids pMTL520 and pCB3 utilise the replicon of the *Clostridium butyricum* plasmid pCB101 (Minton and Morris, 1981). The selective marker of pCB3 is the pAMB1 *erm* gene (Em^R), that of pMTL520 the

Clostridium perfringens *tetP* gene (Tc^R), while pMTL500ET specifies both resistance genes.

In the vast majority of cases, no *C. sporogenes* colonies resistant to either Tc or Em were obtained. A number of putative transformants did result from experiments involving BM1769, 1776, 1783 and 1706, and the plasmid pMTL500ET, and BM1783 and the plasmid pCB3. Subsequent small scale isolation procedures undertaken on representative colonies failed to reveal the presence of extrachromosomal DNA in the resultant cleared lysates. Furthermore, the lysates from the putative pMTL500ET were incapable of transforming competent *E. coli* to Ap^R. In contrast, 8 Ap^R transformants were obtained using the BM1783 lysate derived from the putative pCB3 transformant. Although all 8 *E. coli* transformants were shown to contain plasmid DNA, only 1 gave a restriction pattern characteristic of pCB3. In further tests, radiolabelled pCB3 DNA was used in a Southern blot experiment against total DNA isolated from the putative BM1783 transformant. No positive signal was detected.

Attempts to obtain further transformants of either of the 5 *C. sporogenes* strains proved unsuccessful. This included experiments in which the strains were grown in media containing 2% glycine, prior to the preparation of "competent" cell suspensions. Electrotransformation as a means of eliciting DNA transfer was therefore abandoned in favour of conjugative procedures.

Conjugative DNA transfer

The ability of IncP plasmids to effect the mobilisation of co-resident cloning vectors from an *E. coli* donor to a variety of Gram-positive recipient is now well documented (Trieu-Cuot et al., 1987). Indeed, previous studies have shown that when pMTL500E or pCB3 is endowed with the transfer origin of the IncPII plasmid RK2 (*oriT*), then conjugative transfer of the resultant plasmids (pCTC1 and pCTC501, respectively) was demonstrable between a Tra⁺ (RK2) *E. coli* donor and *C. acetobutylicum* NCIB 8052 (Williams et al., 1990a & b). To test the applicability of this method to *C. sporogenes* all 20 strains were used as recipients in filter matings using the Tra⁺ *E. coli* host SM17 containing either pCTC1 or pCTC501. Strains were examined in batches of 5, and every experiment included a filter mating employing *C. acetobutylicum* NCIB 8052 as the control. In no instance were any Em^R colonies recovered from a mating involving a *C. sporogenes* as the recipient. In contrast, in every batch of matings, the *C. acetobutylicum* control experiment consistently gave Em^R transconjugants.

2.3 AN EXPRESSION SYSTEM FOR *CLOSTRIDIUM ACETOBUTYLICUM*

2.3.1 Summary

The inability to effect the transfer of plasmid DNA to any strain of *C. sporogenes* has led to the adoption of *C. acetobutylicum* NCIB 8052 as the proposed host for production of BoNT toxoid. Efforts have focused on deriving a regulated expression system based on the previously constructed *fac* promoter, composed of the transcriptional initiation signals of the *C. pasteurianum* ferredoxin gene in which a synthetic *lac* operator sequence has been inserted immediately 3' to the +1 nucleotide. Using an *E. coli* model system, transcription from *fac* has been shown to be subject to the regulatory control of the *E. coli lacI* gene product. Subsequent efforts have concentrated on attempting to obtain *lacI* expression in *C. acetobutylicum* NCIB 8052. Insertion of a *lacI* gene derivative, which had been transcriptionally coupled to a Gram-positive vegetative promoter, into the *fac* based expression vector pMTL500F proved impossible, due to structural instability. Attempts to construct a second plasmid compatible with pMTL500F, into which *lacI* may be inserted, have been hampered by lack of an alternative selectable marker to that (*erm*) carried by pMTL500F. Although *tetP* appeared to express in *C. acetobutylicum*, transformants could not be directly selected on the basis of Tc^R. Selection for acquisition of a *cat* gene on the basis of thiamphenicol resistance also proved inappropriate with this clostridial strain. The cloning of restriction fragments encoding staphylococcal determinants of Ap resistance resulted in structural rearrangements/ deletions in the resultant recombinant plasmids. Progress was made in devising a means of targeting DNA to the host chromosome. Evidence was obtained suggesting that a replication-impaired plasmid (pMTL513E) carrying an internal portion of the *C. acetobutylicum gutD* gene readily becomes integrated into the host chromosome. This observation opens up the route for obtaining a *C. acetobutylicum* derivative in which the *lacI* gene is integrated into the chromosome, preferably by recombinational events involving double cross-overs. In the absence of antibiotic resistance markers, selection for such an event may be achieved by cointegration of the *C. pasteurianum leuB* gene in a NCIB 8052 LeuB⁻ derivative, SBA9.

2.3.2 Results and Discussion

Transcription from the clostridial fac promoter is regulated by LacI

The failure to achieve demonstrable DNA transfer into any of the *C. sporogenes* strains

tested necessitated the use of *C. acetobutylicum* as an alternative host. This clostridial species has a number of advantages over *C. sporogenes*. On a practical level, we have already developed the necessary means of manipulating this species. Equally as important, this species has no known association with human disease and should therefore command a lower Access factor in any proposed recombinant experiments. The proposed expression of BoNT gene subfragments can therefore be undertaken at a lower category of containment. Furthermore, parallel studies undertaken in this laboratory have resulted in the construction of an expression cartridge, similar to that proposed for the *C. sporogenes* *rrn* promoter, based on the transcriptional signals of the ferredoxin (Fd) gene of *Clostridium pasteurianum* (Minton et al.,




Fig. 12. The *Clostridium acetobutylicum* expression vector, pMTL500F. Plasmid pMTL500F was constructed by replacing the *lac po* region of pMTL500E with the indicated modified (see Minton et al., 1990a) Fd promoter. During its derivation, plasmid pMTL500F also acquired the pSC101 stability function, *par* (PAR). The ATG tri-nucleotide of the indicated *Nde*I restriction recognition site corresponds to the AUG translational start codon of *lacZ'*, and is immediately preceded by the Fd ribosome binding site (RBS). The multiple cloning sites (MCS) are those of pMTL20 (Chambers et al., 1988).

1990a). This expression cartridge was shown to direct the expression of the pC194 *cat* gene such that the encoded protein represented between 3 and 7% of the cells' soluble protein

(Minton et al., 1990b) In more recent studies this promoter has been modified by the precise insertion of an *E. coli lac* operator sequence at the Fd + 1, and the resultant promoter derivative (designated *fac*) inserted into pMTL500E in place of the natural promoter of the *lacZ'* gene. Thus, in the derived plasmid, pMTL500F (Fig. 12), expression of *lacZ'* is under the transcriptional control of *fac* (Minton et al., 1990b).




Fig. 13. Inducible expression of the pC194 *cat* gene cloned in pMTL500E and pMTL500F. A promoterless copy of the pC194 *cat* gene, excised from pMTL20C (Swinfield et al., 1990) as a 0.8 kb *MnII* fragment, was inserted into the *SmaI* site of pMTL500E and pMTL500F, such that transcription was dependent on the *lac* or Fd promoter, respectively. The two recombinant plasmids were independently introduced into *E. coli* TG1 containing the *lacI^r*-encoding plasmid pNM52 (Gilbert et al., 1986), and the two clones grown in 2XYT broth to an OD₄₅₀ of 0.6. At this point expression was induced by addition of IPTG (indicated by an) to a final concentration of 1 mM. CAT activity of cells carrying pMTL500E (●) or pMTL500F (■) is expressed as % cell soluble protein. The culture OD₄₅₀ of cells carrying pMTL500E and pMTL500F is indicated by (○) and (□), respectively.

The presence of the *lac* operator should enable transcription from *fac* to be blocked by binding of the LacI protein. Derepression may subsequently be achieved by the addition of the inducer IPTG. Such inducibility requires that the *lacI* gene is efficiently expressed in the recombinant host employed. In our preliminary studies the pC194 *cat* gene was inserted into pMTL500F and the resultant plasmid introduced into an *E. coli* host which carried the *lacI* gene on a co-resident, compatible plasmid, pNM52 (Gilbert et al., 1986). When cells carrying both

plasmids were grown overnight in the presence or absence of IPTG, significant repression of *cat* expression was evident. Thus non-induced cells synthesised CAT to levels of approx. 1.0% of the cells' soluble protein, compared to the 13% levels attained in cells supplemented with IPTG.

A clearly idea of the degree of repression/inducibility was obtained by undertaking the experiment outlined in Fig. 13. Cells carrying pNM52 and either pMTL500E*cat* or pMTL500F*cat* were grown in rich media to mid exponential phase when IPTG was added to both cultures, at a final concentration of 1.0 mM. It can be seen that prior to induction no CAT activity was detectable. Following the addition of IPTG, rapid induction of *cat* expression was evident. Most encouragingly the degree of repression/ induction exhibited by the natural *lac* promoter (pMTL500*cat*) and the *fac* promoter (pMTL500F*cat*) was identical.

Towards expression of lacI in C. acetobutylicum

Having established that *fac* can be regulated by LacI repressor protein, efforts focused on effecting expression of this gene in *C. acetobutylicum* NCIB 8052. Previous workers have elicited expression of *lacI* in the Gram-positive bacterium *B. subtilis* by coupling transcription to a *Bacillus* vegetative promoter and inserting the modified gene either, into the backbone of the expression vector itself (pREP8), or into a second compatible plasmid (LeGrice et al., 1987). Therefore, initially we attempted to insert a pREP8-derived *lacI* encoding DNA fragment into the specially constructed unique *EcoRV* site of the expression vector pMTL500F. Accordingly a 1.4 kb *EcoRI*-*PvuI* fragment carrying *lacI* was excised from pREP8), blunt-ended by treatment with T4 DNA polymerase and ligated to *EcoRV* cleaved pMTL500F. Subsequent analysis of the recombinant plasmids obtained, however, indicated that severe structural rearrangements had occurred.

The alternative strategy of inserting this gene into a second co-resident plasmid requires the availability of a plasmid which is not only compatible with regard to replication apparatus (ie., different replicon), but in addition, to prevent intermolecular recombination, should not possess DNA homology. We have previously constructed (Minton et al., 1988) such a prototype vector(pMTL520) which, with reference to pMTL500F, fulfils all these criteria. Thus whereas pMTL500F is based on the *E. coli* ColE1 replicon, pMTL520 utilises the p15a replicon. Similarly, pMTL500F uses the pAMB1 replicon and *erm* gene, whereas pMTL520 makes use of the pCB101 replicon and *tetP* from a *C. perfringens* R-factor. However, repeated attempts to transform *C. acetobutylicum* to Tc^R (10 µg/ml) were unsuccessful, raising doubts as to the suitability of pMTL520 for use in *C. acetobutylicum*.

The tetP gene cannot be used as a selective marker in C. acetobutylicum

Two explanations may be evoked to explain the inability of pMTL520 to transform *C. acetobutylicum*. Either: (i) although pMTL520 confers resistance to Tc on *E. coli* hosts, the *tetP* gene does not function in *C. acetobutylicum*, or; (ii) the pCB101 replicon became inactivated during the construction of the vector. To clarify the situation a second plasmid was constructed by inserting the *tetP* gene into pMTL500E (Fig. 11). This new plasmid, pMTL500ET, therefore encodes both *erm* and *tetP*. Confirmation that both antibiotic resistance genes function in a Gram-positive host was obtained by transforming *B. subtilis*, where it proved possible to select for transformants either on the basis of Em^R or Tc^R. Transformation of *C. acetobutylicum* was then repeated using pMTL500ET DNA with selection on plates either containing Em (10 µg/ml) or Tc (10 µg/ml). Transformants were only obtained on the former plates. Furthermore these Em^R transformants subsequently failed to grow on agar medium containing 10 µg/ml Tc.

TETRACYCLINE CONCENTRATION	GROWTH of NCIB 8052	
	Plasmid-free	+ pMTL500ET
0	+++	+++
1 µg/ml	-	+++
2.5 µg/ml	-	++
5 µg/ml	-	+
10 µg/ml	-	-

Table 6. Growth of NCIB 8052 and a pMTL500ET transformant on media supplemented with Tc

The inability of pMTL500ET Em^R transformants to grow on plates containing Tc prompted an examination of the level of susceptibility of *C. acetobutylicum* to this antibiotic over a range of concentrations. The results are illustrated in Table 6. *C. acetobutylicum* was found to be incapable of growth at levels as low as 1 µg/ml. In contrast, a pMTL500ET transformant (selected on the basis of resistance to Em) was capable of normal growth at this level of antibiotic, reduced growth at Tc concentrations of 2.5 µg/ml and sparse growth on agar containing 5 µg/ml Tc. The transformation experiment with pMTL500ET was therefore repeated, with selection on plates containing 1.0 and 2.5 µg/ml of Tc. Although Tc^R colonies were obtained at both concentrations, an almost equivalent number were obtained using cells which received no plasmid DNA. Furthermore, replica plating of the putative transformants

onto agar media supplemented with Em revealed that no colony had become Em^R . Raising the level of Tc in agar plates to 4 $\mu\text{g/ml}$ appeared to prevent any growth of cells which did not receive plasmid DNA. However, the low number of colonies obtained from cells treated with pMTL500ET DNA were all found to be Em^S , indicating they were not true transformants. Indeed, no extrachromosomal DNA was evident when appropriate cleared lysates were analysed by agarose gel electrophoresis. It was concluded that, although *tetP* appears to confer Tc^R on *C. acetobutylicum* once the plasmid carrying it has become established in the cell, it is not possible to directly select for Tc^R in transformation experiments.

Alternative selective markers

Because the availability of only one selective marker (*erm*) places severe limitations on any future recombinant manipulations in *C. acetobutylicum*, the elucidation of a second marker is a matter of some importance. Reliance on commonly used genes specifying resistance to Cm and Km have previously proven inappropriate for this *Clostridium* spp. (see Oultram et al., 1987). Some authors have circumvented the problems associated with the anaerobic reduction of chloramphenicol by using thiamphenicol, eg., in *Clostridium thermohydrosulfuricum* (Soutschek-Bauer et al., 1985). The possibility of using this analogue for selection of pMTL500Fcat transformants was therefore explored. As growth experiments demonstrated that *C. acetobutylicum* NCIB 8052 grew on levels of thiamphenicol up to and including 100 $\mu\text{g/ml}$, a concentration of 150 $\mu\text{g/ml}$ was used in selective plate. However, although pMTL500Fcat electrotransformants could be readily selected on the basis of Em^R , no colonies were obtained on the plates containing thiamphenicol.

A further potential marker gene that could be employed is a gene specifying resistance to ampicillin. Such a determinant encoding a typical "pBR322-like" β -lactamase from a *Staphylococcus aureus* plasmid (pS1) has recently been sequenced (East and Dyke, 1989). However, although the sequenced *bla* gene alone is sufficient for Ap^R in *E. coli*, a region of DNA 5' to the gene is required for resistance in staphylococci. A plasmid carrying the whole determinant necessary for Ap^R in a Gram-positive bacterium, pAE306, was obtained from Dr K Dyke at Oxford and a 4.0 kb fragment excised and inserted into pMTL520. Although the resultant plasmid conferred Ap^R on an *E. coli* host, Ap^R transformants of *C. acetobutylicum* were not obtained. Subsequent dialogue with Dr Dyke's laboratory indicated that rearrangements of the Ap^R determinant of plasmid pAE306 had occurred. A second plasmid was therefore obtained, pSLJ104, which carried the entire Tn552 transposon, encompassing *blaZ*, on a 6.0 kb *Bam*HI fragment. However, attempts to insert this fragment into the polylinker site of pMTL500E consistently resulted in recombinant plasmids in which structural rearrangements/ deletions were apparent.

The gut operon as a potential site for homologous integration

The facility for effecting the insertion of heterologous DNA into the host chromosome, by homologous recombination, offers considerable advantages in any proposed programme of strain manipulation. The principal attraction is that it circumvents the problems of recombinant segregational instability commonly associated with autonomous vectors. Thus, the ability to integrate genes into the *C. acetobutylicum* chromosome offers great potential in the future generation of strains expressing *bot* gene subfragments. Such technology, however, also provides the facility for generating a strain in which *lacI* has been inserted into the chromosome.

Integrative strategies require two components: (i) a cloned region of the host chromosome, to provide homology for recombination, the disruption of which is not deleterious to cell growth, and; (ii) a vector delivery system, the replication properties of which favour integration. We have just completed sequencing the *gut* operon of *C. acetobutylicum*, which encodes the genes necessary for glucitol (sorbitol) transport/metabolism. The operon (Fig. 14) has the same overall arrangement as *E. coli* (Yamada and Saier, 1987), but additionally contains a gene coding for a protein exhibiting homology to the ORF U polypeptide of




Fig. 14. The arrangement of genes in the *C. acetobutylicum* *gut* operon, and the position of equivalent genes in *E. coli* and *B. subtilis*. The encoded polypeptides of similarly shaded ORFs exhibit amino acid homology. The encoded enzymes are: *gutA*, PTS-IItm; *gutB*, Enzyme IIItm; *gutD*, glucitol-6-P dehydrogenase, and; *orfU* & *orfX* (*C. acetobutylicum*), transaldolase. A sequence error in the illustrated *B. subtilis* region means that *orfY* and *tsr* form only 1 ORF, and encodes aldolase (J Cary, personal communication).

B. subtilis (Trach et al., 1988). Recently ORF U polypeptide has been shown to exhibit distant homology to yeast transaldolase (J Clary, personal communication), providing tentative evidence that the *C. acetobutylicum* ORF X gene product may be transaldolase (Fig. 14). The *gutD* gene (encoding glucitol dehydrogenase) seems an ideal target for integration as it is not normally required by the host, and presents an easy test for successful integration, ie., inability to grow on sorbitol as the carbon source.

Integrative vectors

Integrative vectors are ideally based on plasmids which are temperature sensitive for replication. Such a vector, containing cloned region of the host genome, may be introduced into the target cell and selected at a temperature permissive for replication. Successfully transformed cells may then be grown at the non-permissive temperature in the presence of the antibiotic to which the vector confers resistance. Under these conditions plasmids are




Fig. 15. Cloning vectors based on the *pAMB1* replicon. All plasmids were generated by insertion of the indicated *pAMB1*-derived DNA (see Swinfield et al., 1990) fragment (bold line) into the *NheI* site of pMTL20E (thin line). The *lacZ'* is therefore functional (blue colonies in the presence of XGal) unless inactivated by subsequent insertion of heterologous DNA into the polylinker region. Plasmid pMTL500E is a high copy number plasmid, while pMTL502E and pMTL513E have a low copy number. The general purpose cloning vectors pMTL500E and pMTL502E exhibit moderate segregational stability. Plasmid pMTL513E exhibits extreme instability in both *B. subtilis* and *C. acetobutylicum* (see Table 7).

rapidly lost from the population with the result that the only cells which can grow in the presence of the antibiotic are those in which chromosomal integration of the plasmid element occurs. With this in mind, attempts have been made to isolate a temperature-sensitive replication mutant of pMTL500E (Fig. 15) by *in vitro* mutagenesis. Plasmid DNA was incubated with hydroxylamine, as previously described (Minton, 1984), and the resultant damaged DNA used to transform *E. coli* cells to Ap^R. Total transformant colonies were then pooled (by flooding the agar plates with media), bulk plasmid DNA prepared and used to transform *B. subtilis* to Em^R at 28°C. Colonies obtained were then replica plated onto fresh plates and grown for 24 h at 42°C. To date approx. 5,000 *B. subtilis* colonies have been screened in this manner, but only one putative ts mutant has been isolated. Subsequent characterisation of this transformant, however, indicated that ts defect resided in the adenine methylase enzyme (*erm* gene). Screening is continuing.

In parallel to the above, integrative experiments have proceeded with the replication-impaired vector pMTL513E (Fig. 15). This vector was derived by replacing the pAMB1 replication region of pMTL500E with the pAMB1 replicon of plasmid pMTL20CB13 (Swinfield et al., 1990). Because this replicon contains a deletion which extends into the replication origin, the efficiency of replication is severely impaired. Thus, in the presence of the selective antibiotic *B. subtilis* cells carrying this plasmid exhibit a 4-fold increase in doubling time, while in the absence of selective pressure plasmid-free segregants arise at an extremely high frequency (Swinfield et al., 1990). A 336 bp *NheI-SpeI* restriction fragment, internally located within the *gutD* structural gene were therefore cloned into the polylinker of pMTL513E at its unique *XbaI* site. The plasmid obtained, pJEN2, was transformed into *C. acetobutylicum* NCIB 8052 and Em^R transformants selected. Interestingly, pJEN2 transformed *C. acetobutylicum* at a significantly higher frequency (5-fold higher) than the progenitor vector, pMTL513E, presumably as a result of carrying a homologous chromosomal DNA

PLASMID	% OF CELLS RESISTANT TO ERYTHROMYCIN	
	10 generations	20 generations
pMTL531E	99.5	99
pMTL500E	66	44
pJEN2	0.4	0.01
CHR::pJEN2	100	100

Table 7. Segregational instability of pMTL513E during growth of *C. acetobutylicum* in the absence of antibiotic selection. Cells were grown in 2 X YTG for 10 and 20 generations and the % of cells no longer Em^R estimated by deriving colony viable counts on media with and without Em. For comparative purposes, the results with pMTL500E and a stabilised derivative, pMTL531E (Swinfield et al., 1991), are shown. Preliminary results indicate the putative integrant (CHR::pJEN2) is 100% stable.

insert. A transformant containing the plasmid was then grown for 50 generations in the absence of antibiotic selection, before Em was added to the medium, the culture incubated for




Fig. 16. Schematic representation of Cambell-like integration of pMTL513E containing a *gutD* subfragment into the *C. acetobutylicum* chromosome.

a further 8 hours and cells plated out on agar medium containing Em^R. As can be seen from Table 7, pJEN2 was rapidly lost from the cell population in the absence of selective pressure. Indeed, when the culture was plated out after 50 generations only 15 Em^R colony was obtained. Using appropriate minimal agar plates, the cells from all 15 colonies were subsequently shown to be incapable of growth on sorbitol as the sole carbon source. Furthermore preliminary experiments indicated that loss of Em^R no longer occurs when the cells are grown in the absence of antibiotic (Table 7). Both observations strongly indicate that integration of pJEN2 has occurred at the *gutD* gene.

A schematic representation of how pJEN2 could become inserted at the *gutD* locus of the *C. acetobutylicum* chromosome by Cambell integration is shown in Fig. 16. In this scheme a single recombinational cross-over results in duplication of the homologous *gutD* gene segment, concomitant with inactivation of the chromosomal copy. Double cross-overs would not inactivate the gene, nor result in a strain exhibiting segregational stabilisation of the Em^R determinant. The experiments necessary to confirm that such an event has occurred are currently being undertaken. In addition to classical DNA/DNA hybridisation experiments, oligonucleotides have been synthesised specific to sequences in pMTL513E and *gutB*. The PCR amplification of a DNA fragment of the correct size (see Fig. 16) will confirm integration.

CONCLUSIONS

1] CLONING OF *Clostridium botulinum* NEUROTOXIN GENES

Status: The entire nucleotide sequences of the *botB* and *botE* genes have been determined, and the majority of the *botF*. The recombinant clone necessary to elucidate the missing 60 codons from the 3' end of *botF* is available, a region encompassing the missing 20 codons from the 5' end of the gene has yet to be obtained. Additionally, only 50% of the currently available *botF* sequence has been determined from more than one PCR amplified fragment. Initial attempts to PCR amplify regions of *botG* have proven unsuccessful.

Future aims: The immediate objectives of this aspect of the proposal are to complete the *botF* cloning/ nucleotide sequence determination. The missing 5' end will be obtained by cloning an appropriate PCR amplified fragment. Oligonucleotides will be based on known *botF* sequence and a sequence from the 5' non-coding region of *botE*. Authentication of the sequence will be performed by sequencing independently isolated duplicate clones to those already isolated, and where necessary, additional clones. Once completed, efforts will focus on *botG*, when PCR primers will be synthesised based on nucleotide sequences capable of encoding amino acid motifs which are highly conserved between all 6 characterised neurotoxins.

2] EXPRESSION SYSTEM DEVELOPMENT

Status: Attempts to elicit the transfer of plasmid DNA vectors into 20 different strains of *Clostridium sporogenes*, by either electro-transformation or by conjugative mobilisation, have met with no success. Rather than persevere with this *Clostridium sp.*, the genetically amenable species *Clostridium acetobutylicum* NCIB 8052 has been chosen as an alternative host for the future expression of *bot* gene subfragments. Efforts have focused on imposing regulatory control on the *fac* promoter system by seeking to obtain expression of *lacI* in *C. acetobutylicum*. Preliminary attempts have been unsuccessful largely due to the lack of a second selectable genetic marker. Circumvention of this problem should prove possible following the demonstration that it is possible to "force" the integration of recombinant DNA into the host genome.

Future aims: In the immediate future we will continue to address the problem of a second selectable marker. Alternative *cat* and *tet* genes have been requested from other groups working in the field, most significantly pAM81-based vectors carrying the streptococcal *tetM* gene, which has been shown to be selectable in *C. acetobutylicum* DSM 1731 (P. Durre, personal communication). The highest priority, however, will be given to integrative studies. The type of integration achieved to date (involving a single cross-over) is not ideal, as the duplication of homologous DNA will result in excision of the inserted recombinant vector at an equivalent frequency to insertion. Stable integrants require double cross-overs, in which reciprocal exchange of DNA occurs between the plasmid and chromosomal copies. The necessary constructs to achieve this are currently being constructed (ie., the entire *gutD* gene in which a central portion of the structural gene is deleted and replaced with a heterologous gene). Using this strategy, we will endeavour to integrate a DNA fragment composed of *lacI* and the *C. pasteurianum* *leuB* gene, arranged in tandem, at the *gutD* locus of a *leuB* mutant of *C. acetobutylicum*, SBA9. The *C. pasteurianum* *leuB* gene has previously been shown to convert this *C. acetobutylicum* auxotroph to prototrophy (Oultram et al., 1988a; 1988b). Thus, SBA9 cells transformed with pMTL513E carrying DNA encompassing *gutD::lacI/leuB* will initially be selected on the basis of Em^R. Thereafter, they will be grown in the absence of antibiotic selection for 50 generations, and then plated on minimal media lacking leucine. Leu⁺, Em^S colonies which can no longer grow on sorbitol as a carbon source should represent clones in which integration of *lacI/leuB* has occurred by a double cross-over.

Once a *C. acetobutylicum* *lacI*⁺ host has been obtained, it should prove possible to regulate the expression of heterologous genes which have been transcriptionally coupled to the *fac* promoter of pMTL500F. At this stage we will begin inserting various regions of the *botA* gene into pMTL500F. Constructs will be made in *E. coli*, where any deleterious effects which may be associated with expression in this organism may be avoided by repressing transcription from *fac* by using a *lacI*⁺ host (ie., containing pNM52, Gilbert et al., 1986). Once obtained, plasmids will be transformed into SBA9::*lacI* where expression may be elicited by the addition of IPTG.

In general terms the objectives with regard to expression system development remain on schedule. Thus, although there has been a change of host organism, the current status exactly matches that alluded to in the grant application SOWs. On the *bot* gene cloning programme, progress is significantly ahead of schedule, a situation largely due to the participation of additional manpower resource.

REFERENCES

- Abraham, L.J. & Rood J.I. (1985) *Plasmid* 13, 155-162.
- Ahnert-Higler, G., Weller, U., Dauzenroth, M.E., Habermann, E. & Gratzl, M. (1989) *FEBS Microbiol. Lett.* 242, 245-248.
- Allen, S.P. & Blaschek, H.P. (1988) *Appl. Environ. Microbiol.* 54, 2322-2324.
- Blaustein, R. O., Germann, W. J., Finkelstein, A. & Dasgupta, B. R. (1987) *FEMS Microbiol. Letts.* 226, 115-120.
- Binz, T., Kurazono, H., Wille, M., Frevert J., Wernars, K. & Niemann (1990) *J. Biol. Chem.* 265, 9153-9158.
- Binz, T., Kurazono, H., Popoff, M.R., Eklund, M.W., Sakaguchi, G., Kozaki, S., Krieglstein, K., Henschen, A., Gill, D.M. and Niemann, H. (1990) *Nucleic Acids Res.* 18, 5556.
- Binz, T., O. Grebenstein, H. Kurazono, J. Thierer, U. Eisel, K. Wernars, M. Popoff, S. Mochida, B. Poulain, L. Tauc, S. Kozaki, and H. Niemann. (1991) Molecular biology of the L chains of clostridial neurotoxins. Abstracts of the 5th European Workshop on Bacterial Protein Toxins, Veldhoven, Holland, July 1991.
- Bittner, M.A., DasGupta, B.R. & Holz, R.W. (1989) *J. Biol. Chem.* 264, 10354-10360.
- Boquet, P. & Duflot, E. (1982) *Proc. Natl. Acad. Sci. USA* 79, 7614-7618.
- Bruand, C., Ehrlich, S.D. & Janniere, L. (1991). *EMBO J.* 10, 2171-2177.
- Brehm, J.K., Salmond, G.P.C. & Minton, N.P. (1987) *Nucl. Acids Res.* 15, 3177.
- Brehm, J.K., Chambers, S.P., Bown, K.J., Atkinson, T. & Minton, N.P. (1992) *Appl. Microbiol. Biotechnol.* 36, 358-363.k
- Cato EP & Stackebrandt E (1989) in *Clostridia*, (Minton, N.P. & Clarke, D.J., eds), pp. 1-26, Plenum Publishing, New York.
- Carter, P., Bedouelle, H. and Winter, G. (1985) *Nucleic Acids Res.* 13, 4431-4443.
- Chassy, B.M., Mercenier, A. & Flickinger, J. (1988) *Trends Biotechnol.* 6, 303-309.

- Chambers S. P., Prior, S. E., Barstow, D. A. & Minton, N. P. (1988) *Gene* 68, 139-149.
- Chen, E.Y. & Seeburg, P.H. (1985) *DNA* 4, 165-170.
- Chou, P.Y. & Fassman, G.D. (1978) *Adv. Enzym.* 47, 45-
- DasGupta, B.R. & Datta, A. (1987) *Fedn. Proc. Fedn. Am. Socs. Exp. Biol.* 45, 2289.
- DasGupta, B.R. & Datta, A. (1988) *Biochimie (Paris)* 70, 811-817.
- Dasgupta, B.R. (1990) *J. Physiol. (Paris)* 84, 220-228.
- Dolly, J.O., Black, J., Williams, R.S. & Melling, J. (1984) *Nature* 307, 457-460.
- Eckert, K.A. & Kunkel, T.A. (1991) *PCR Methods and Applications 1*, 17-24.
- Eisel, U., Jarausch, W., Goretzki, K., Henschen, A., Engels, J., Weller, U., Hudel, M., Habermann, E. & Niemann, H. (1986) *EMBO J.* 5, 2495-2502.
- Evans, D.M., Williams, R.S., Shone, C.C., Hambleton, P., Melling, J., & Dolly, J.O. (1987) *Eur. J. Biochem.* 154, 409-416.
- Fairweather, N.F., Lyness, V.A., Pickard, D.J., Allen, G. and Thomson, R.O. (1986) *J. Bacteriol.* 165, 21-27.
- Fairweather, N.F., Lyness, V.A. and Maskell, D.J. (1987) *Infect. Immunity* 55, 2541-2545.
- Fairweather, N. F. & Lyness, V. (1986) *Nucleic Acid Res.* 14, 7809-7812.
- Fujii, N., Kimura, K., Murakami, T., Indoh, I., Yashiki, T., Tsuzuki, K., Yokosawa, N. & Oguma, K. (1990) *Microbiol. Immunol.* 34, 1041-1047.
- Garnier, J., Osguthorpe, D.J. & Robson, B. (1973) *J. Mol. Biol.* 120, 97-117
- Garnier, T. & Cole, S.T. (1988) *Plasmid* 19, 134-150.
- Gilbert H.J., Blazek, R, Bullman, H.M.S. & Minton N.P. (1986) *J. Gen. Microbiol.* 132, 151-160.
- Gill, D.M. (1978) in *Bacterial toxins and cell membranes* (Jeljaszewicz, J. & Wadstrom, T., eds), pp. 291-332, Academic Press, Inc., New York.
- Grosjean, H. & Fiers, W. (1982) *Gene* 18, 199-209.
- Grunstein, M. & Hogness, D. (1975) *Proc. Natl. Acad. Sci. USA* 72, 3961-3965.
- Habermann, E. & Dreyer, F. (1986) *Curr. Top. Microbiol. Immunol.* 129, 93-179.

- Hall, J.D., McCroskey, L., Pincomb, B.J. & Hatheway, C.L. (1985) *J. Clin. Microbiol.* 21, 654-655
- Hatheway, C.L., McCroskey, L.M., Lombard, G.L. & Dowell, Jr., V.R. (1981) *J. Clin. Microbiol.* 14, 607-611.
- Hauser, D., Eklund, M.W., Kurazono, H., Binz, T., Niemann, H., Gill, D.M. Boquet, P & Popoff, M.R. (1990) *Nucleic Acids Res.* 18, 4924.
- Higgins, D.G. & Sharp, P.M. (1988) *Gene* 73, 237-244.
- Hoch, D. H., Romero-Mira, M., Ehrlich, B. E., Finkelstein, A., Dasgupta, B. R. & Simpson, L. L. (1985) *Proc. Natl. Acad. Sci. USA* 82, 1692-1696.
- Holmes, D.S., and Quigley, M. (1981) *Anal. Biochem.* 114, 193-197.
- Kozaki, S., Kamata, Y., Takafumi, N., Ogasawara, J. & Sakaguchi, G. (1986) *Infect. Immun.* 52, 786-791.
- Kozaki, S., Ogaswara, J., Shimote, Y., Kamata, Y. & Sakaguchi, G. (1987) *Infect. Immun.* 55, 3051-3056.
- Kozaki, S., Miki, A., Kamata, Y., Ogasawara, J. & Sakaguchi, G. (1989) *Infect. Immun.* 57, 2634-2639.
- Kyte, J. & Doolittle R.F. (1982) *J. Mol. Biol.* 157, 105-132.
- Le Grice, S.F.J. Beuck, V. & Mous, J. (1987) *Gene* 55, 95-103.
- Lucansky, J.B., Muriana, P.M. & Klaenhammer, T.R. (1988) *Mol. Microbiol.* 2, 637-646.
- Maisey, E. A., Wadsworth, J. D. F., Poulain, B., Shone, C. C., Melling, J., Gibbs, P., Tauc, L. & Dolly, J. O. (1988) *Eur. J. Biochem.* 177, 683-691.
- Marmur, J. (1961) *J. Mol. Biol.* 3, 208-218.
- McCroskey, L.M., Hatheway, C.L. Fenicia, L., Pasolini, B. & Aureli, B. (1985) *J. Clin. Microbiol.* 23, 210-202.
- McDonnell, M.W., Simon, M.N. & Studier, F.W. (1977) *J. Mol. Biol.* 110, 119-146.
- Mead, D.A., Pey, N.K., Herrbstadt, C., Marcil, R.A. & Smith, L.M. (1991) *Biotechnol.* 9, 657-663.
- Minton, N.P. (1984) *Gene* 31, 269-273.
- Minton, N.P. & Morris, J.G. (1981) *J. Gen. Microbiol.* 127, 325-331.

- Minton, N.P., Atkinson, T. & Sherwood, R.F. (1983a) *J. Bacteriol.* 156, 1222-1227.
- Minton, N.P., Marsch, J.L. & Atkinson, T. (1983b) *J. Appl. Bacteriol.* 55, 445-452.
- Minton, N. P., Atkinson, T., Bruton, C. J. & Sherwood, R. F. (1984) *Gene* 31, 31-38.
- Minton, N.P., Bullman, H.M.S., Scawen, M.D., Atkinson, T. & Gilbert, H.J.. (1986) *Gene* 46, 25-35.
- Minton, N.P. & Oultram, J.D. (1988) *Microbiol. Sci.* 5, 310-315.
- Minton, N.P., Brehm, J.K., Oultram, J.D., Swinfield, T.J. & Thompson, D.E. (1988) in *Anaerobes Today* (Hardie, J.M. & Borellio, S.P., eds.), pp. 125-134. John Wiley & Sons, Chichester, UK.
- Minton, N.P., Brehm, J.K., Oultram, J.D., Swinfield, T.J., Schimming, S., Whelan, S.M., Thompson, D.E., Young, M. & Staudenbauer, W.L. (1990a). In "Proceedings of the 6th International Symposium on Genetics of Industrial Microorganisms" Vol. II (H. Heslot, J. Davies, J. Florent, L. Bobichon, G. Durand and L. Penasse, Eds.), pp. 759-770. Société Française de Microbiologie, Strasbourg.
- Minton, N.P., Brehm, J.K., Oultram, et al. (1990b) in *Clinical and Molecular Aspects of Anaerobes* Borriello, S.P., ed.) pp. 187-201, Wrightson Biomedical Publishing Ltd, Petersfield.
- Mochida, S., Poulain, B., Weller, U., Habermann, E. & Tauc, L. (1989) *FEBS Microbiol. Lett.* 253, 47-51.
- Morris, N.P., Consiglio, E., Kohn, L.D., Habig, W.H., Hardegree, M.C. & Helting, T.B. (1981) *J. Biol. Chem.* 255, 6071-6076.
- Notermans, S., Kozaki, Y. Kamata U, & Sakaguchi, G. (1984) *J. Med. Sci. Biol.* 37, 138-140.
- O'Brien, R.W., and Morris, J.G. (1971) *J. Gen. Microbiol.* 68, 307-318.
- Oultram, J.D., Davies, A., and Young, M. (1987) *FEMS Microbiol. Lett.* 42, 113-119.
- Oultram, J.D., Loughlin, M., Swinfield, T.J., Brehm, J.K., Thompson, D.E. & Minton, N.P. (1988a) *FEMS Microbiol. Letts.* 56, 83-88.
- Oultram, J.D., Peck, H., Brehm, J.K., Thompson, D., Swinfield, T.J. & Minton, N.P. (1988b) *Mol. Gen. Genet.* 214, 177-179.
- Poulain, B., Mochida, S., Wadsworth, J.D.F., Weller, U., Høgy, B., Habermann, E., Dolly, J.O. & Tauc, L. (1990) *J. Physiol. Paris.* 84, 247-261.

- Poulain, B., Mochida, S., Weller, U., Høgy, B., Habermann, E., Wadsworth, J.D.F., Shone, C.C., Dolly, J.O. & Tauc, L. (1991) *J. Biol. Chem.* 266, 9580-9585.
- Reed, K.C., & Mann, D.A. (1985) *Nucl. Acids Res.* 13, 7207-7221.
- Roberts, I., Holmes, W.M. & Hylemon, P.B. (1986) *Appl. Environ. Microbiol.* 52, 197-199.
- Rood, J.I. & Cole, S.T. (1991) *Microbiol. Rev.* 55, 621-648.
- Sambrook, J., Fritsch, E.F., and Maniatis, T. (1989) *Molecular Cloning. A laboratory manual*, second edition. Cold Spring harbour, New York.
- Sanger, F., Coulson, A.R., Barrell, B.G., Smith, A.J.H. & Roe, B.A. (1980) *J. Mol. Biol.* 143, 161-178.
- Sathyamoorthy, V. & Dasgupta, B.R. (1985) *J. Biol. Chem.* 260, 10461-10466.
- Schmidt, J.J., Sathyamoorthy, V. & Dasgupta, B.R. (1985) *Arch. Biochem. Biophys.* 238, 544-548.
- Shone, C.C. & Hambleton, P. (1989) in *Clostridia* (Minton, N.P. & Clarke, D.J., eds) pp. 265-291, Plenum Publishing Inc., New York.
- Shone, C. C., Hambleton, P. & Melling, J. (1985) *Eur. J. Biochem.* 151, 75-82.
- Shone, C. C., Hambleton P. & Melling, J. (1987) *Eur. J. Biochem.* 167, 175-180.
- Singh, B.R., Wasacz, F.M., Strand, S., Jakobsen, R.J. & Dasgupta, B.R. (1990) *J. Prot. Chem.* 9, 705-713.
- Simpson, L.L. (1981) *Pharmacol. Rev.* 33, 155-188.
- Simpson, L.L. (1986) *Ann. Rev. Pharmacol. Toxicol.* 26, 427-453.
- Simpson, L.L. (1989) in *Botulinum Neurotoxin and Tetanus Toxin*, (Simpson, L.L. ed.) pp. 153-178, Academic Press Inc., San Diego.
- Soutschek-Bauer, E., Hartl, L., and Staudenbauer, W.L. (1985) *Biotechnol. Lett.* 7, 705-710.
- Siechner, B., Weller, U., Habermann, E., Gratzl, M. & Ahnert-Higler, G. (1989) *FEBS Microbiol. Lett.* 255, 391-394.
- Sugiyama, H. (1980) *Microbiol. Rev.* 44, 419-448.
- Swinfield, T.J., Oultram, J.D., Thompson, D.E., Brehm, J.K. & Minton, N.P. (1989) *Gene* 87, 79-90.

- Swinfield, T-J., Janniere, L., Ehrlich, S.D. & Minton, N.P. (1991) *Plasmid* 26, 209-221.
- Tabor, S. & Richardson, C.C. (1987) *Proc. Natl. Acad. Sci. USA* 84, 4767-4771.
- Thompson, D.E., Brehm, J.K., Oultram, J.D., Swinfield, T-J., Shone, C.C., Atkinson, T., Melling, J. & Minton, N.P. (1990) *Eur. J. Biochem.* 189, 73-81.
- Trach, K., Chapman, J.W., Piggot, P., LeCoq, D. & Hoch, J.A. (1988) *J. Bacteriol.* 170, 4194-4208.
- Trieu-Cuot, P., Carlier, C., Martin, P. & Courvalin, P. (1987) *FEMS Microbiol. Lett.* 48, 289-294.
- von Eichel-Streiber, C., Suckau, D., Wachter, M. & Hadding, U. (1989) *J. Gen. Microbiol.* 135, 55-64.
- Weickert, M.J. Chambliss G.H. and Sugiyama, H. (1986) *Appl. Environ. Microbiol.* 51, 52-56.
- Welloner, H.H. (1982) *Rev. Physiol. Biochem. Pharmacol.* 93, 1-68.
- Wernars, K. & Notermans, S. (1990) in *Bacterial Protein Toxins* (Rappuoli, R., Alouf, J.E., Falmagne, P., Fehrenbach, F.J., Freer, J., Gross, R., Jeljaszewicz, J., Montecucco, C., Tomasi, M., Wadstrom, T & Witholt, B., eds), pp. 113-114, Gustav Fischer Verlag, Stuttgart.
- Williams, D.R., Young, D.I., Oultram, J.D., Minton, N.P., and Young, M. (1990a) in *Clinical and molecular aspects of anaerobes* (Borriello, S.P., ed.), pp. 239-246, Wrightson Biomedical Publishing Ltd, Petersfield.
- Williams, D.R., Young, D.I., and Young, M. (1990b) *J. Gen. Microbiol.* 136, 819-826.
- Yamada, M. & Saier, M. (1987) *J. Biol. Chem.* 262, 5455-5463 .
- Yanisch-Perron, C., Vieira, J. & Messing, J. (1985) *Gene* 33, 103-119.
- Young, M., Staudenbauer, W.L. & Minton, N.P. (1989) in *Clostridia* (Minton, N.P. & Clarke, D.J., eds) pp. 63-103, Plenum Publishing Inc., New York.
- Young, M., Minton, N. P. & Staudenbauer, W. L. (1989) *FEMS Microbiol. Rev.* 63, 1-25.